Microbe Alteration of Active Substances

✅ Microbes that affect active substances (drugs, traditional medicines/herbs, bioactive compounds, environmental chemicals)

Click "Microbe Name" to access detailed information about the microbe active substance interaction profile and microbe abundance in human gut.

Microbe Name	Substance Name	Substance Category	Substance Subcategory	Metabolism Type	Metabolites	Effects on Substance	Experimental Organism	Experimental Disease Condition	Mebabolism Mechanism	Mebabolism Outcome	References
Unidentified gut microbes	Baicalin	Herbal Substance	Medicinal Herbal Compounds	Hydrolysis; deglycosylation	Baicalein; oroxylin A	Increase Efficacy	n.a.	Inflammation; diabetes mellitus; tumor	n.a.	Increased activity	PMID: 26569070; PMID: 22516259; PMID: 24947972; PMID: 24033282
Unidentified gut microbes	Olsalazine	Therapeutic Substance	Approved Drug	Azo reduction	5-aminosalicylclic acid	Increase Efficacy; Increase Toxicity	n.a.	Inflammatory diseases(ulcerative colitis; Crohn’s disease; rheumatoid arthritis)	n.a.	Increased activity or causing side effects(anorexia and nausea)	PMID: 26569070; PMID: 11230497
Unidentified gut microbes	Nizatidine	Therapeutic Substance	Approved Drug	N-oxide bond cleavage	n.a.	Decrease Efficacy	n.a.	Peptic ulcer disease	n.a.	Decreased intestinal absorption and systemic bioavailability	PMID: 26569070; PMID: 13481854
Unidentified gut microbes	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	N-oxide bond cleavage	n.a.	Decrease Efficacy	n.a.	Peptic ulcer disease	n.a.	Decreased intestinal absorption and systemic bioavailability	PMID: 26569070; PMID: 13481854
Unidentified gut microbes	Flucytosine	Therapeutic Substance	Approved Drug	Deamination	5-fluorouracil	Increase Efficacy; Increase Toxicity	n.a.	n.a.	n.a.	Increased activity or toxicity	PMID: 26569070; PMID: 14768038
Unidentified anaerobic bacterium	Sulfinpyrazone	Therapeutic Substance	Approved Drug	Reduction	sulindac sulfide; sulinpyrzone sulfide	Increase Efficacy	n.a.	n.a.	n.a.	Increased activity	PMID: 26569070; PMID: 18927500
Unidentified anaerobic bacterium	Sulindac	Therapeutic Substance	Approved Drug	Reduction	sulindac sulfide; sulinpyrzone sulfide	Increase Efficacy	n.a.	n.a.	n.a.	Increased activity	PMID: 26569070; PMID: 18927500
Unidentified gut microbes	Insulin human	Therapeutic Substance	Approved Drug	Proteolysis	Peptides	Decrease Efficacy	n.a.	Type 1 diabetes mellitus	n.a.	Decreased activity	PMID: 26569070; PMID: 21051639
Unidentified gut microbes	Loperamide oxide	Therapeutic Substance	Investigational Drug	Reduction	Loperamide	Increase Efficacy	n.a.	n.a.	n.a.	Increased activity	PMID: 26569070; PMID: 21148486
Unidentified gut microbes	Nitrazepam	Therapeutic Substance	Approved Drug	Nitroreduction	7-aminonitrazepam	Increase Toxicity	n.a.	Moderate to severe insomnia	n.a.	Inducing teratogenicity	PMID: 26569070; PMID: 21156650
Unidentified gut microbes	Nitroglycerin	Therapeutic Substance	Approved Drug	Denitration	Glyceryl-1,3-dinitrate; glyceryl-1,2-dinitrate; glyceryl-1-mononitrate; glyceryl-2-mononitrate	Decrease Efficacy	n.a.	Angina pectoris	n.a.	Decreased activity	PMID: 26569070; PMID: 22902524
Unidentified gut microbes	Dihydroxyphenylalanine (DOPA)	Therapeutic Substance	n.a.	Dehydroxylation	m-tyramine; m-hydroxylphenylacetic acid	Increase Efficacy	n.a.	Parkinson’s disease	n.a.	Increased activity	PMID: 26569070; PMID: 24264989
Unidentified gut microbes	Indomethacin	Therapeutic Substance	Approved Drug	Deconjugation	n.a.	Decrease Efficacy; Increase Toxicity	n.a.	n.a.	n.a.	Decreased activity; increased side effects(diarrhea; anorexia; weight loss)	PMID: 26569070; PMID: 24264990
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Hydrolysis; demethylation; hydroxylation/dehydroxylation; β-oxidation	Lactic acid; 3-hydroxybutanoic acid; cyclohexanecarboxylic acid; 2-hydroxyvaleric acid	n.a.	n.a.	Cardiovascular disease	n.a.	Altering its lipid-lowering activity	PMID: 26569070; PMID: 5913083
Unidentified gut microbes	Risperidone	Therapeutic Substance	Approved Drug	Ring cleavage; hydroxylation	Benzisoxazole ring scission; Benzisoxazole ring hydroxylation	Increase Toxicity	n.a.	n.a.	n.a.	Inducting symptoms of Parkinson’s disease	PMID: 26569070; PMID: 6836275
Unidentified gut microbes	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Amine formation; hydrolysis	p-aminphenyl-2-amino-1； 3-propanediol	Increase Toxicity	n.a.	n.a.	n.a.	Inducing bone marrow aplasia	PMID: 26569070; PMID: 8706020
Clostridium sp.	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	Reduction; phenolic ring opening	Dihydrodaidzein; equol; O-desmethylanolensin(ODMA）	Increase Efficacy	n.a.	Osteoporosis; menopausal symptoms; cardiovascular diseases; obesity	n.a.	Increased activity	PMID: 26569070
anaerobic bacterium 'strain 7'	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	Reduction; phenolic ring opening	Dihydrodaidzein; equol; O-desmethylanolensin(ODMA）	Increase Efficacy	n.a.	Osteoporosis; menopausal symptoms; cardiovascular diseases; obesity	n.a.	Increased activity	PMID: 26569070
Bacteroides uniformis	Genistein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	Hydrogenation	Production of 5-hydroxyequol	n.a.	n.a.	Obesity; type 2 diabetes	n.a.	n.a.	PMID: 26569070
Bacteroides	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	Hydrolysis	Compound K	Increase Efficacy	n.a.	Inflammation; tumor	n.a.	Increased activity	PMID: 26569070
Bifidobacterium	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	Hydrolysis	Compound K	Increase Efficacy	n.a.	Inflammation; tumor	n.a.	Increased activity	PMID: 26569070
Eubacterium sp. GLH	Glycyrrhizin	Herbal Substance	Medicinal Herbal Compounds	Hydrolysis	18-β-glycyrrhetinic acid	Increase Efficacy	n.a.	Inflammation	n.a.	Increased activity	PMID: 26569070
Pseudocera	Hesperidin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Deglycosylation	Hesperetin	Increase Efficacy	n.a.	n.a.	n.a.	Increased activity	PMID: 26569070
Klebsiella pneumoniae	Lactulose	Therapeutic Substance	Approved Drug	Hydrolysis	Monosaccharides; lactate, acetate; butyrate	n.a.	n.a.	n.a.	n.a.	Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli)	PMID: 26569070
Enterococcus faecalis	Lactulose	Therapeutic Substance	Approved Drug	Hydrolysis	Monosaccharides; lactate, acetate; butyrate	n.a.	n.a.	n.a.	n.a.	Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli)	PMID: 26569070
Cronobacter sakazakii	Lactulose	Therapeutic Substance	Approved Drug	Hydrolysis	Monosaccharides; lactate, acetate; butyrate	n.a.	n.a.	n.a.	n.a.	Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli)	PMID: 26569070
Enterococcus casseliflavus	Lactulose	Therapeutic Substance	Approved Drug	Hydrolysis	Monosaccharides; lactate, acetate; butyrate	n.a.	n.a.	n.a.	n.a.	Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli)	PMID: 26569070
Bacteroides	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Thiazole ring opening	levametabol-I; levametabol-II; levametabol-III	Increase Efficacy	n.a.	Colon cancer	n.a.	Increased activity	PMID: 26569070
Clostridium sp.	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Thiazole ring opening	levametabol-I; levametabol-II; levametabol-III	Increase Efficacy	n.a.	Colon cancer	n.a.	Increased activity	PMID: 26569070
Clostridia	Metamfetamine	Therapeutic Substance	Approved Drug	Demethylation	Amphetamine; norephedrine; an unknown metabolite	Decrease Efficacy	n.a.	n.a.	n.a.	Decreased activity	PMID: 26569070
Enterococcus	Metamfetamine	Therapeutic Substance	Approved Drug	Demethylation	Amphetamine; norephedrine; an unknown metabolite	Decrease Efficacy	n.a.	n.a.	n.a.	Decreased activity	PMID: 26569070
Lactobacillus	Metamfetamine	Therapeutic Substance	Approved Drug	Demethylation	Amphetamine; norephedrine; an unknown metabolite	Decrease Efficacy	n.a.	n.a.	n.a.	Decreased activity	PMID: 26569070
Unidentified anaerobic bacterium	Omeprazole	Therapeutic Substance	Approved Drug	Reduction	corresponding sulfide metabolites	Decrease Efficacy	n.a.	Gastric ulcer	n.a.	Decreased activity	PMID: 26569070
Enterococcus casseliflavus	Quercetin-3-glucoside	Herbal Substance; Dietary Substance	Medicinal Herbal Compounds; Dietary Compounds	Deglycosylation	Butyrate; acetate; 3,4-dihydroxyphenylacetic acid	n.a.	n.a.	Cardiovascular disease; tumors	n.a.	n.a.	PMID: 26569070
Eubacterium ramulus	Quercetin-3-glucoside	Herbal Substance; Dietary Substance	Medicinal Herbal Compounds; Dietary Compounds	Deglycosylation	Butyrate; acetate; 3,4-dihydroxyphenylacetic acid	n.a.	n.a.	Cardiovascular disease; tumors	n.a.	n.a.	PMID: 26569070
Clostridioides difficile	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	O-Sulfation; C-S cleavage of acetaminophen-3-cysteine	acetaminophen sulfate; glucuronide	Increase Efficacy; Decrease Toxicity	n.a.	n.a.	Microbial product(p-cresol) could alter the ratio of metabolites	Altered activity or toxicity	PMID: 26569070
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Reduction	Dihydrodigoxin; dihydrodigoxigenin	Decrease Efficacy	Human	Heart disease	n.a.	Decreased cardiac activity	PMID: 26569070
Unidentified gut microbes	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Dehydroxylation	m-tyrosine; m-tyramine; m-hydroxyphenylacetic acid	Decrease Efficacy	n.a.	Parkinson's disease	n.a.	Decreased activity	PMID: 26569070
Unidentified gut microbes	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Reduction	N-(2-hydroxyethyl)-oxamic acid; acetamide	Increase Toxicity	n.a.	n.a.	n.a.	Probably increase its liver toxicity	PMID: 26569070
Bacteroides fragilis	Sorivudine	Therapeutic Substance	Investigational Drug	Hydrolysis	(E)-5-(2-bromovinyl) uracil	Increase Toxicity	n.a.	n.a.	Metabolites can inactivate a key liver enzyme	Lead to lethal toxicity when co-administered with 5-fluorouracil	PMID: 26569070; PMID: 27591027
Bacteroides thetaiotaomicron	Sorivudine	Therapeutic Substance	Investigational Drug	Hydrolysis	(E)-5-(2-bromovinyl) uracil	Increase Toxicity	n.a.	n.a.	Metabolites can inactivate a key liver enzyme	Lead to lethal toxicity when co-administered with 5-fluorouracil	PMID: 26569070; PMID: 27591027
Bacteroides uniformis	Sorivudine	Therapeutic Substance	Investigational Drug	Hydrolysis	(E)-5-(2-bromovinyl) uracil	Increase Toxicity	n.a.	n.a.	Metabolites can inactivate a key liver enzyme	Lead to lethal toxicity when co-administered with 5-fluorouracil	PMID: 26569070; PMID: 27591027
Bacteroides vulgatus	Sorivudine	Therapeutic Substance	Investigational Drug	Hydrolysis	(E)-5-(2-bromovinyl) uracil	Increase Toxicity	n.a.	n.a.	Metabolites can inactivate a key liver enzyme	Lead to lethal toxicity when co-administered with 5-fluorouracil	PMID: 26569070; PMID: 27591027
Bacteroides eggerthii	Sorivudine	Therapeutic Substance	Investigational Drug	Hydrolysis	(E)-5-(2-bromovinyl) uracil	Increase Toxicity	n.a.	n.a.	Metabolites can inactivate a key liver enzyme	Lead to lethal toxicity when co-administered with 5-fluorouracil	PMID: 26569070; PMID: 27591027
Unidentified gut microbes	Mesalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Microbial arylamine N-acetyltransferases	Differences in gut microbial metabolism contribute to variations in drug efficacy	PMID: 11344150; PMID: 26972811
Unidentified gut microbes	Azo dyes	Environmental Chemicals	Industrial Chemicals and Pollutants	n.a.	n.a.	n.a.	n.a.	n.a.	Reduce azo bond	n.a.	PMID: 26972811; PMID: 14489780
Unidentified gut microbes	Enrofloxacin	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	Mouse	Enrofloxacin-or vancomycin-treated	Microbial fermentation of carbohydrates is disrupted	Decrease concentrations of amino acids and SCFAs;increase oligosaccharide levels	PMID: 18698804; PMID: 26972811
Unidentified gut microbes	Vancomycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	Enrofloxacin-or vancomycin-treated	Microbial fermentation of carbohydrates is disrupted	Decrease concentrations of amino acids and SCFAs;increase oligosaccharide levels	PMID: 18698804; PMID: 26972811
Unidentified gut microbes	Pentobarbital	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Animal model	Germ-free,colonized	n.a.	Germ-free animals are more efficient at metabolizing drug	PMID: 19742318; PMID: 26972811
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Human	n.a.	n.a.	Treatment is positively associated with the production by the microbiota(lithocholic acid, taurolithocholic acid and glycolithocholic acid)	PMID: 22022402; PMID: 26972811
Unidentified gut microbes	Oxaliplatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Production of reactive oxygen species	Induces apoptosis	PMID: 24264989; PMID: 26972811
Firmicutes	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	n.a.	Promote the translocation of bacteria into secondary lymphoid organs	Limit tumour growth	PMID: 24264990; PMID: 26972811
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	dihydrodigoxin	Decrease Efficacy	n.a.	n.a.	Cgr operon	n.a.	PMID: 6836275; PMID: 26972811
Unidentified gut microbes	Heterocyclic amines	Environmental Chemicals	Unclassified Substance	n.a.	n.a.	n.a.	n.a.	n.a.	Β-glucuronidases	Microbiota contribute to associations between the risk of CRC and the intake of heterocyclic amines	PMID: 8055651; PMID: 26972811
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Microbial β-glucuronidase,liberate the sugar moiety from SN-38G	Re-activate the drug causing increased toxicity(towards intestinal epithelial cells);exacerbate the diarrhoea	PMID: 8891470; PMID: 26972811
Unidentified gut microbes	7-ethyl-10-hydroxycamptothecin	Therapeutic Substance	Investigational Drug	n.a.	SN-38G; ;cyanuric acid	Increase Toxicity	Animal model	Germ-free,colonized	n.a.	Metabolites are harmful to the host	PMID: 26972811
Fusobacteria	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Microbial metabolite p-cresol competes with drug	Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite NAPQI	PMID: 26972811
Clostridioides difficile	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Microbial metabolite p-cresol competes with drug	Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite NAPQI	PMID: 26972811
Bacteroidetes	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Microbial metabolite p-cresol competes with drug	Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite NAPQI	PMID: 26972811
Actinobacteria	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Microbial metabolite p-cresol competes with drug	Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite NAPQI	PMID: 26972811
Bifidobacterium	Anti-PD-L1 therapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Increase the efficacy of PD-1	PMID: 26972811
Staphylococcus	Anti-TNF antibobies	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Therapy is accompanied by a substantial increase in the abundance of bacteria	PMID: 26972811
Aspergillus nidulans	Black tea	Dietary Substance	Drinks	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Increase the abundance of A. muciniphila	PMID: 26972811
Proteobacteria	Choline-containing compounds	Environmental Chemicals	Unclassified Substance	n.a.	n.a.	n.a.	n.a.	n.a.	Microbial glycyl radical enzymes	Associate with the risk of cardiovascular disease	PMID: 26972811
Firmicutes	Choline-containing compounds	Environmental Chemicals	Unclassified Substance	n.a.	n.a.	n.a.	n.a.	n.a.	Microbial glycyl radical enzymes	Associate with the risk of cardiovascular disease	PMID: 26972811
Bacteroides fragilis	CTLA-4 blockade	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Blockade immunotherapy	PMID: 26972811
Bacteroides thetaiotaomicron	CTLA-4 blockade	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Blockade immunotherapy	PMID: 26972811
Enterococcus faecium	Daidzin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	equol	n.a.	n.a.	n.a.	Glycosidic cleavage and reduction	n.a.	PMID: 26972811
Bifidobacterium sp.	Daidzin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	equol	n.a.	n.a.	n.a.	Glycosidic cleavage and reduction	n.a.	PMID: 26972811
Lactobacillus mucosae	Daidzin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	equol	n.a.	n.a.	n.a.	Glycosidic cleavage and reduction	n.a.	PMID: 26972811
Eggerthella sp.	Daidzin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	equol	n.a.	n.a.	n.a.	Glycosidic cleavage and reduction	n.a.	PMID: 26972811
Unidentified gut microbes	Dietary phosphatidylcholine	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Bacteria provide a link for drugs	PMID: 26972811
Gordonibacter	Ellagic acid	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolize ellagitannins	PMID: 26972811
Aspergillus nidulans	Grape-derived polyphenols	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Increase the abundance of A. muciniphila	PMID: 26972811
Unidentified gut microbes	Heterocyclic amine 2-amino-3-methylimidazo[4,5-f]quinoline (IQ)	Environmental Chemicals	Unclassified Substance	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reactivate the compound	PMID: 26972811
Campylobacter	Isoaminile	Therapeutic Substance	Approved Drug	n.a.	cyclohexylamine	n.a.	Animal model	n.a.	n.a.	Exhibit toxicity	PMID: 26972811
Escherichia	Isoaminile	Therapeutic Substance	Approved Drug	n.a.	cyclohexylamine	n.a.	Animal model	n.a.	n.a.	Exhibit toxicity	PMID: 26972811
Enterococcus	Isoaminile	Therapeutic Substance	Approved Drug	n.a.	cyclohexylamine	n.a.	Animal model	n.a.	n.a.	Exhibit toxicity	PMID: 26972811
Clostridium	Isoaminile	Therapeutic Substance	Approved Drug	n.a.	cyclohexylamine	n.a.	Animal model	n.a.	n.a.	Exhibit toxicity	PMID: 26972811
Corynebacterium	Isoaminile	Therapeutic Substance	Approved Drug	n.a.	cyclohexylamine	n.a.	Animal model	n.a.	n.a.	Exhibit toxicity	PMID: 26972811
Firmicutes	Isoflavones	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolites bind to oestrogen receptors	May elicit protective effects against breast cancer	PMID: 26972811
Bacteroidetes	Isoflavones	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolites bind to oestrogen receptors	May elicit protective effects against breast cancer	PMID: 26972811
Actinobacteria	Isoflavones	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolites bind to oestrogen receptors	May elicit protective effects against breast cancer	PMID: 26972811
Firmicutes	Lignans	Herbal Substance; Dietary Substance	Medicinal Herbal Compounds; Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolites bind to oestrogen receptors	May elicit protective effects against breast cancer	PMID: 26972811
Bacteroidetes	Lignans	Herbal Substance; Dietary Substance	Medicinal Herbal Compounds; Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolites bind to oestrogen receptors	May elicit protective effects against breast cancer	PMID: 26972811
Actinobacteria	Lignans	Herbal Substance; Dietary Substance	Medicinal Herbal Compounds; Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolites bind to oestrogen receptors	May elicit protective effects against breast cancer	PMID: 26972811
Unidentified gut microbes	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	Decrease Efficacy	Animal model	Germ-free,colonized	Conversion into a downstream metabolite with reduced bioactivity	n.a.	PMID: 26972811
Unidentified gut microbes	NSAIDs	Therapeutic Substance	Drug Class	n.a.	SN-38G; ;cyanuric acid	Increase Toxicity	Animal model	Germ-free,colonized	n.a.	Metabolites are harmful to the host	PMID: 26972811
Unidentified gut microbes	Phenoxyethanol	Therapeutic Substance	Approved Drug	n.a.	SN-38G; ;cyanuric acid	Increase Toxicity	Animal model	Germ-free,colonized	n.a.	Metabolites are harmful to the host	PMID: 26972811
Raoultella terrigena	Phenoxyethanol	Therapeutic Substance	Approved Drug	n.a.	cyanuric acid	n.a.	Animal model	n.a.	n.a.	Lead to increased kidney damage	PMID: 26972811
Raoultella terrigena	Phenoxyethanol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolism by the bacteria	Lead to kidney stones	PMID: 26972811
Akkermansia muciniphila	Polyphenols	Herbal Substance; Dietary Substance	Medicinal Herbal Compounds; Dietary Compounds	n.a.	n.a.	n.a.	Mouse	Fed high-fat diets	Couple with substantial sevenfold-to-tenfold blooms of drug	Limit the risk of systemic inflammation	PMID: 26972811
Clostridiales bacterium	Saccharin	Therapeutic Substance; Dietary Substance; Herbal Substance	Investigational Drug; Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms	n.a.	Increase the abundance of bacteria	PMID: 26972811
Unidentified gut microbes	Secoisolariciresinol	Therapeutic Substance	Investigational Drug	n.a.	enterodiol,enterolactone	n.a.	n.a.	n.a.	n.a.	Product the cancer-protective compounds	PMID: 26972811
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Bioavailability	n.a.	n.a.	Modulate the expression of host transporters,or directly compete with host transporters	Contribute to the absorption of simvastatin	PMID: 26972811
Unidentified gut microbes	Sulfanilamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Efficacy	Animal model	Germ-free,colonized	Conversion to bioactive form	Contribute to therapeutic concentrations	PMID: 26972811
Enterococcus faecalis	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	Antibiotic-treated or germ-free;convention	n.a.	Result in drug cleavage	PMID: 26972811
Lactobacillus sp.	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	Antibiotic-treated or germ-free;convention	n.a.	Result in drug cleavage	PMID: 26972811
Bacteroides sp.	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	Antibiotic-treated or germ-free;convention	n.a.	Result in drug cleavage	PMID: 26972811
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Efficacy	Animal model	Germ-free,colonized	Conversion to bioactive form	Contribute to therapeutic concentrations	PMID: 26972811
Faecalibacterium prausnitzii	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Human	Kidney transplant recipient	n.a.	The abundance of the gut bacterium has a positive correlation with an increase in tacrolimus dosing	PMID: 26972811
Unidentified gut microbes	TMAO	Environmental Chemicals	Human Metabolite	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Bacteria provide a link for drugs	PMID: 26972811
Clostridiales bacterium	Xylitol	Therapeutic Substance; Herbal Substance		n.a.	n.a.	n.a.	Mouse	Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms	n.a.	Increase the abundance of bacteria	PMID: 26972811
Bacteroidales	Carboxymethylcellulose	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	n.a.	Decrease the abundance of Bacteroidales;increase the abundance of mucolytic bacteria	The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome	PMID: 26972811
[Ruminococcus] gnavus	Carboxymethylcellulose	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	n.a.	Decrease the abundance of Bacteroidales;increase the abundance of mucolytic bacteria	The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome	PMID: 26972811
Bacteroidales	Polysorbate 80	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	n.a.	Decrease the abundance of Bacteroidales;increase the abundance of mucolytic bacteria	The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome	PMID: 26972811
[Ruminococcus] gnavus	Polysorbate 81	Environmental Chemicals	Industrial Chemicals and Pollutants	n.a.	n.a.	n.a.	Mouse	n.a.	Decrease the abundance of Bacteroidales;increase the abundance of mucolytic bacteria	The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome	PMID: 26972811
Escherichia coli	Glucuronidated compound	Environmental Chemicals	Unclassified Substance	n.a.	n.a.	n.a.	Mouse	Convention,germ-free	Β-glucuronidases	Reactivate the toxic compound and augment genotoxicity	PMID: 26972811
Unidentified gut microbes	Sulfanilamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	triamino benzene,sulfanilamide	Increase Efficacy	n.a.	n.a.	Reduce azo bond	Activate drug	PMID: 26972811
Enterococcus faecalis	Secoisolariciresinol	Therapeutic Substance	Investigational Drug	n.a.	enterodiol and entero lactone	Increase Efficacy	Rat	Germ-free,or germ-free colonized with a bacterial consortium	Metabolism by bacteria	Protective effects against breast cancer	PMID: 26972811
Eubacterium limosum	Secoisolariciresinol	Therapeutic Substance	Investigational Drug	n.a.	enterodiol and entero lactone	Increase Efficacy	Rat	Germ-free,or germ-free colonized with a bacterial consortium	Metabolism by bacteria	Protective effects against breast cancer	PMID: 26972811
[Clostridium] scindens	Secoisolariciresinol	Therapeutic Substance	Investigational Drug	n.a.	enterodiol and entero lactone	Increase Efficacy	Rat	Germ-free,or germ-free colonized with a bacterial consortium	Metabolism by bacteria	Protective effects against breast cancer	PMID: 26972811
Blautia producta	Secoisolariciresinol	Therapeutic Substance	Investigational Drug	n.a.	enterodiol and entero lactone	Increase Efficacy	Rat	Germ-free,or germ-free colonized with a bacterial consortium	Metabolism by bacteria	Protective effects against breast cancer	PMID: 26972811
Eggerthella lenta	Secoisolariciresinol	Therapeutic Substance	Investigational Drug	n.a.	enterodiol and entero lactone	Increase Efficacy	Rat	Germ-free,or germ-free colonized with a bacterial consortium	Metabolism by bacteria	Protective effects against breast cancer	PMID: 26972811
Lactonifactor longoviformis	Secoisolariciresinol	Therapeutic Substance	Investigational Drug	n.a.	enterodiol and entero lactone	Increase Efficacy	Rat	Germ-free,or germ-free colonized with a bacterial consortium	Metabolism by bacteria	Protective effects against breast cancer	PMID: 26972811
Unidentified gut microbes	Diclofenac	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Microbial β-glucuronidase	Cause mitochondrial and endo plasmic reticulum stress, compromise mucosal integrity and promote inflammation	PMID: 26972811
Unidentified gut microbes	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Microbial β-glucuronidase	Cause mitochondrial and endo plasmic reticulum stress, compromise mucosal integrity and promote inflammation	PMID: 26972811
Unidentified gut microbes	Ketoprofen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Microbial β-glucuronidase	Cause mitochondrial and endo plasmic reticulum stress, compromise mucosal integrity and promote inflammation	PMID: 26972811
Bacteroides	Saccharin	Therapeutic Substance; Dietary Substance; Herbal Substance	Investigational Drug; Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms	n.a.	Increase the abundance of bacteria	PMID: 26972811
Unidentified gut microbes	Tempol	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	Increase the abundance of Bacteroidetes;decrease the abundance of Firmicutes	PMID: 26972811
Firmicutes	Tempol	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reduce members of the genus Lactobacillus	PMID: 26972811
Bacteroides	Xylitol	Therapeutic Substance; Herbal Substance		n.a.	n.a.	n.a.	Mouse	Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms	n.a.	Increase the abundance of bacteria	PMID: 26972811
Lactobacillus	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Decrease expression of genes involved in antimicrobial defence	Nearly eradicated the lactobacilli	PMID: 26972811
Clostridioides difficile	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Piglet	n.a.	n.a.	Promote colonization by opportunistic pathogens	PMID: 26972811
Candida albicans	Amoxicillin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Piglet	n.a.	n.a.	Promote colonization by opportunistic pathogens	PMID: 26972811
Clostridioides difficile	Antibiotic	Therapeutic Substance	Drug Class	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	n.a.	Cause antibiotic-associated diarrhoea(AAD);pseudomembranous colitis(can cause death)	PMID: 26972811
Candida albicans	Cefoperazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Total number of bacteria is reduced;overgrowth of C.albicans	Allergic-airways diease develops after challenge with mould spores	PMID: 26972811
Lactobacillus	Cephalosporins	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Suppression of lactocilli and bifidobacterial;overgrowth of C.albicans	Increase susceptibility to asthma	PMID: 26972811
Bifidobacterium	Cephalosporins	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Suppression of lactocilli and bifidobacterial;overgrowth of C.albicans	Increase susceptibility to asthma	PMID: 26972811
Candida albicans	Cephalosporins	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Suppression of lactocilli and bifidobacterial;overgrowth of C.albicans	Increase susceptibility to asthma	PMID: 26972811
Lactobacillus	Kanamycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Total number of anaerobes is reduced	Clinical scores for atopic dermatitis are higher	PMID: 26972811
Bifidobacterium sp.	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	More bifidobacterium spp.	PMID: 26972811
Gram-negative bacterium B1G-1A	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	n.a.	Reduce expression of the gene encoding REG3γ	n.a.	PMID: 26972811
Gram-negative bacterium B1G-1A	Neomycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	n.a.	Reduce expression of the gene encoding REG3γ	n.a.	PMID: 26972811
Salmonella enterica subsp. enterica serovar Typhimurium	Streptomycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	Streptomycin treated	Butyrate contribute to the increased infiltration of neutrophils	Result in an increased inflammatory state	PMID: 26972811
Unidentified vaginal microbes	Unspecified antibiotic	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Loss of vaginal lactobacilli;and overgrowth of C.albicans	n.a.	PMID: 26972811
Candida albicans	Unspecified antibiotic	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Loss of vaginal lactobacilli;and overgrowth of C.albicans	n.a.	PMID: 26972811
Unidentified gut microbes	Vancomycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Gram-negatinve populations are depleted(not being restricted by vancomycin)	PMID: 26972811
Gram-negative bacterium B1G-1A	Vancomycin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	n.a.	Reduce expression of the gene encoding REG3γ	n.a.	PMID: 26972811
Unidentified gut microbes	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	hydroxyiminonizatidine	n.a.	n.a.	n.a.	Cleavage on an N-oxide bond	n.a.	PMID: 27485182; PMID: 11955801
Unidentified gut microbes	Nabumetone	Therapeutic Substance	Approved Drug	n.a.	4-(6-methoxy-2-naphthyl)-butan-2-ol (reduced nabumetone)	Decrease Efficacy	n.a.	n.a.	n.a.	Cause lower absorbtion of nabumetone and lower its bioavailability;[drug interaction:erythromycin and tetracycline suppresses the reduction of digoxin]	PMID: 23584048; PMID: 27485182
Unidentified gut microbes	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	a phosphorylated derivative and active 2-hydroxy lovastatic acid	n.a.	Rat	n.a.	Hydrolyzed	[drug interaction]:antibiotics decreases the bioavailability of the active metabolite	PMID: 27485182; PMID: 24947972
Unidentified gut microbes	Lovastatin related compounds	Therapeutic Substance	n.a.	n.a.	a phosphorylated derivative and active 2-hydroxy lovastatic acid	n.a.	Rat	n.a.	Hydrolyzed	[drug interaction]:antibiotics decreases the bioavailability of the active metabolite	PMID: 27485182; PMID: 24947972
Unidentified gut microbes	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Human; Rabbit	Healthy volunteers and ileostomy patients;/	Microbiota seems to be only site of sulfinpyrazone reduction(in man)	n.a.	PMID: 3630204; PMID: 27485182
Unidentified gut microbes	Sulindac	Therapeutic Substance	Approved Drug	n.a.	sulindac sulfide	n.a.	Human; Rabbit	n.a.	n.a.	n.a.	PMID: 3630204; PMID: 27485182
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid (mesalazine)and sulfapyridine	Decrease Toxicity	n.a.	n.a.	Bacterial azoreductases	Lead to side effect	PMID: 27485182; PMID: 4147555
Unidentified gut microbes	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	p-aminophenyl-2-amin-1,3-propanediol	Increase Toxicity	human	n.a.	n.a.	Produce toxic metabolite related to risk of marrow aplasia	PMID: 27485182; PMID: 4165044
Unidentified anaerobic bacterium	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	N-(2-hydroxyethyl)-oxamic acid and acetamide	n.a.	Rat	Conventional(CV),germ-free(GF)	Reductive modification,disrupt the imidazole ring	n.a.	PMID: 27485182; PMID: 430360
Clostridium perfringens	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	N-(2-hydroxyethyl)-oxamic acid and acetamide	n.a.	Rat	Conventional(CV),germ-free(GF)	Reductive modification,disrupt the imidazole ring	n.a.	PMID: 27485182; PMID: 430360
Unidentified gut microbes	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	m-tyramine and m-hydroxyphenylacetic acid	n.a.	Rat	Conventional,in pathogen free	Dehydroxylation of the catechol ring	Form the metabolites	PMID: 4723308; PMID: 27485182
Unidentified gut microbes	Misonidazole	Therapeutic Substance	Investigational Drug	n.a.	amino derivative	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 6260109; PMID: 27485182
Unidentified gut microbes	Balsalazide	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27485182; PMID: 6345112
Unidentified gut microbes	Clonazepam	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	Germ-free and ex-germ-free	Nitro reduction	n.a.	PMID: 27485182; PMID: 6506755
Unidentified gut microbes	Risperidone	Therapeutic Substance	Approved Drug	n.a.	dihydroxy-risperidone and hydroxyl-ke-to-risperidone	n.a.	Rat	n.a.	n.a.	[drug interaction]:(in the liver)antibiotics decrease the bioavailability of risperidone.	PMID: 27485182; PMID: 7512019
Unidentified gut microbes	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	sulfide metabolites	n.a.	n.a.	n.a.	Reductive metabolism	n.a.	PMID: 27485182; PMID: 7629748
Unidentified gut microbes	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	2-sulfamoylacetylphenol	n.a.	Mouse; Rat; Hamster; Rabbit; Guinea pig	n.a.	Reductive metabolism	[drug interaction]:antibiotics inhibit the urinary and faecal excretion of metabolites	PMID: 9231340; PMID: 27485182
Unidentified gut microbes	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	dihydrodigoxin and dihydrodigoxigenin	Decrease Efficacy	human	n.a.	Formation of inactive metabolites	Have lower cardiac activity	PMID: 27485182; PMID: 7266632
Unidentified gut microbes	Mesalazine	Therapeutic Substance	Approved Drug	n.a.	N-acetyl-5-aminosalicylic acid	n.a.	Human; Rat; Guinea pig; Dog	n.a.	Acetylated by the gut microbiota	n.a.	PMID: 27485182
Unidentified gut microbes	Sulfapyridine	Therapeutic Substance	Approved Drug	n.a.	N-acetyl-5-aminosalicylic acid	n.a.	Human; Rat; Guinea pig; Dog	n.a.	Acetylated by the gut microbiota	n.a.	PMID: 27485182
Clostridioides difficile	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	p-cresol sulfate and phenylacetylglutamine	Increase Toxicity	n.a.	n.a.	O-sulfation; C-S cleavage of acetaminophen-3-cysteine	Increased toxicity	PMID: 27485182
Bacteroides	Lactulose	Therapeutic Substance	Approved Drug	n.a.	fructose and galactose	Increase Efficacy	n.a.	n.a.	Hydrolysis of enzymes of the intestinal bacteria	Lead to laxative effect of lactulose	PMID: 27485182
Lactobacillus	Lactulose	Therapeutic Substance	Approved Drug	n.a.	fructose and galactose	Increase Efficacy	n.a.	n.a.	Hydrolysis of enzymes of the intestinal bacteria	Lead to laxative effect of lactulose	PMID: 27485182
Escherichia coli	Lactulose	Therapeutic Substance	Approved Drug	n.a.	fructose and galactose	Increase Efficacy	n.a.	n.a.	Hydrolysis of enzymes of the intestinal bacteria	Lead to laxative effect of lactulose	PMID: 27485182
Clostridium sp.	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	levametabol-I,levametabol-II,and levametabol-III	Increase Efficacy	human	n.a.	Open thiazole ring	Increased activity;[drug interaction]:antibiotics increase a stronger clinical effect of levamisole	PMID: 27485182
Bacteroidetes	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	levametabol-I,levametabol-II,and levametabol-III	Increase Efficacy	human	n.a.	Open thiazole ring	Increased activity;[drug interaction]:antibiotics increase a stronger clinical effect of levamisole	PMID: 27485182
Escherichia coli ATCC 25922	Nabumetone	Therapeutic Substance	Approved Drug	n.a.	a reduced pharmacologically inactive metabolite	Decrease Efficacy	n.a.	n.a.	n.a.	Cause lower absorbtion and lower bioavailability of the drug	PMID: 27485182
[Clostridium] leptum	Nitrazepam	Therapeutic Substance	Approved Drug	n.a.	7-aminonitrazepam	n.a.	Mouse; Rat	n.a.	Nitro reduction	Produce products with teratogenic effects	PMID: 27485182
Bacteroides sp.	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	(E)-5-(2-bromovinyl) uracil	n.a.	n.a.	n.a.	n.a.	[drug interaction]:metabolites cause toxic level of anticancer drug 5-fluorouracil	PMID: 27485182
Unidentified gut microbes	Neoprontosil	Therapeutic Substance	Approved Drug	n.a.	sulfanilamide	Increase Efficacy	n.a.	n.a.	Reduction of the azo bond by azoreductases of the large intestinal microbiota	Activate prodrug,have antibacterial effect;[drug interaction]:antbiotics suppress the conversion of prontosil	PMID: 27485182
Unidentified gut microbes	Sulfanilamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	sulfanilamide	Increase Efficacy	n.a.	n.a.	Reduction of the azo bond by azoreductases of the large intestinal microbiota	Activate prodrug,have antibacterial effect;[drug interaction]:antbiotics suppress the conversion of prontosil	PMID: 27485182
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	Increase Toxicity	n.a.	n.a.	Β-glucuronidases	Cause diarrhoea;[drug interaction]:(rat)ciprofloxacin and amoxapine can suppress diarrhoea	PMID: 21051639; PMID: 28270698
Unidentified gut microbes	CpG oligodeoxynucleotides	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Mouse	n.a.	Bacteria regulate the immune response to chemotherapy(primes tumour-associated innate myeloid cells for inflammatory cytokine production)	[drug interaction]:antibiotic or germ-free (sterile) status attenuates this response	PMID: 24264989; PMID: 28270698
Unidentified gut microbes	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	Cause commensal bacteria translocation into secondary lymphoid organs;reduce the abundance of lactobacilli and enterococci;[drug interaction]:long-term antibiotics reduce the capacity of cyclophosphamide	PMID: 24264990; PMID: 28270698
Unidentified gut microbes	Doxorubicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	Cause commensal bacteria translocation into secondary lymphoid organs;reduce the abundance of lactobacilli and enterococci;[drug interaction]:long-term antibiotics reduce the capacity of cyclophosphamide	PMID: 24264990; PMID: 28270698
Unidentified gut microbes	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	Decrease Toxicity	n.a.	n.a.	TLR2 signalling and drug transporter p-gp	Bacteria regulate against chemotherapy-induced small bowel injury	PMID: 25589072; PMID: 28270698
Unidentified gut microbes	Ginsenosides	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolized via microbiota from compound K79	Metabolites have anti-proliferative effects in human colon cancer cells;[drug interaction]:co-treatment with 5-FU and its pro-drug intermediate 5’-deoxy-5-fluorouridine,potentiate the anticancer effects	PMID: 25625815; PMID: 28270698
Unidentified gut microbes	CTLA-4 blockade	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Mouse	Specific pathogen-free,germ-free(GF)	n.a.	MCA205 sarcoma progression is not controlled(in germ-free mice;or those treated with broad-spectrum antibiotics)	PMID: 26541610; PMID: 28270698
Mycoplasma hyorhinis	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Bacterium encode a thymidine phosphorylase	Restrict the cytostatic activity of pyrimidine nucleoside analogue compounds	PMID: 28270698
Mycoplasma hyorhinis	Trifluridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Bacterium encode a thymidine phosphorylase	Restrict the cytostatic activity of pyrimidine nucleoside analogue compounds	PMID: 28270698
Bifidobacterium sp.	Anti-PD-L1 therapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Mouse	n.a.	Exhibit the association with antitumour T-cell responses(through dendritic cell activation)	Combination of microbiota and anti-PD-L1 improve tumour control,inducte tumour-specific T cells,increase T cells in the tumour microenvironment	PMID: 28270698
Proteobacteria	Carmustine, Etoposide, Cytarabine and melphalan combination	Therapeutic Substance	Drug Combination	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reducte bacteria that limit inflammation,increase bacteria associated with colitis	PMID: 28270698
Firmicutes	Carmustine, Etoposide, Cytarabine and melphalan combination	Therapeutic Substance	Drug Combination	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reducte bacteria that limit inflammation,increase bacteria associated with colitis	PMID: 28270698
Actinobacteria	Carmustine, Etoposide, Cytarabine and melphalan combination	Therapeutic Substance	Drug Combination	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reducte bacteria that limit inflammation,increase bacteria associated with colitis	PMID: 28270698
Ruminococcus	CpG oligodeoxynucleotides	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 28270698
Alistipes	CpG oligodeoxynucleotides	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 28270698
Burkholderiales	CTLA-4 blockade	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	A cocktail of bacteria ameliorate CTLA-4-blockade-induced subclinical colitis and colon inflammatory scores in antibiotic-treated mice	PMID: 28270698
Bacteroidales	CTLA-4 blockade	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	A cocktail of bacteria ameliorate CTLA-4-blockade-induced subclinical colitis and colon inflammatory scores in antibiotic-treated mice	PMID: 28270698
Segmented filamentous bacteria	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Gram-positive commensals mediate accumulation of TH17 and TH1-cell response	PMID: 28270698
Lactobacillus	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Gram-positive commensals mediate accumulation of TH17 and TH1-cell response	PMID: 28270698
Pseudomonas aeruginosa	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	Fed a diet(high in protein, l-leucine, fish oil and specific oligosaccharides);an isoenergetic control die	n.a.	Reduce incidence and severity of Pseudomonas aeruginosa translocation	PMID: 28270698
Enterococcus hirae	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	Inoculated with MCA205 tumours;microbiota-depleted	As an orchestrator of cyclophosphamide effects	n.a.	PMID: 28270698
Barnesiella intestinihominis	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	Inoculated with MCA205 tumours;microbiota-depleted	As an orchestrator of cyclophosphamide effects	n.a.	PMID: 28270698
Enterococcus hirae	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Lactobacillus murinus	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Lactobacillus johnsonii	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Enterococcus hirae	Doxorubicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Lactobacillus murinus	Doxorubicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Lactobacillus johnsonii	Doxorubicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Unidentified gut microbes	Ellagic acid	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	urolithins	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 28270698
Mycoplasma	Gemcitabine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Pyrimidine nucleoside phosphorylase and cytidine deaminase enzyme	Have deleterious effects on its therapeutic efficacy	PMID: 28270698
Bacteroidetes	Ipilimumab	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Bacterially mediated B vitamin production and polyamine transport deficiencies	Bacteria is associated with increased risk of CTLA‑4 blockade‑induced colitis	PMID: 28270698
Enterobacteriaceae	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	Increase abundance of bacteria	Cause diarrhoea;	PMID: 28270698
Streptococcus thermophilus	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis	PMID: 28270698
Clostridioides difficile	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	Increase abundance of bacteria	Cause diarrhoea;	PMID: 28270698
Lactobacillus acidophilus	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis	PMID: 28270698
Lactobacillus plantarum	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis	PMID: 28270698
Lactobacillus paracasei	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis	PMID: 28270698
Bifidobacterium breve	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis	PMID: 28270698
Bifidobacterium longum	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis	PMID: 28270698
Lactobacillus delbrueckii subsp. bulgaricus	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis	PMID: 28270698
Bifidobacterium longum subsp. infantis	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis	PMID: 28270698
Unidentified gut microbes	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reduce diversity and shift in relative abundance associated with chemotherapy-induced diarrhoea	PMID: 28270698
Unidentified gut microbes	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce microbial abundance(decrease anaerobes and streptococci,relative increase of Bacteroides);change in microbiota is associated with diarrhoea	PMID: 28270698
Bacteroides	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reduce diversity and shift in relative abundance associated with chemotherapy-induced diarrhoea	PMID: 28270698
Bacteroides	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce microbial abundance(decrease anaerobes and streptococci,relative increase of Bacteroides);change in microbiota is associated with diarrhoea	PMID: 28270698
Streptococcus	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reduce diversity and shift in relative abundance associated with chemotherapy-induced diarrhoea	PMID: 28270698
Streptococcus	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Reduce microbial abundance(decrease anaerobes and streptococci,relative increase of Bacteroides);change in microbiota is associated with diarrhoea	PMID: 28270698
Bacteroidetes	Polysaccharides (after cyclophosphamide administration)	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	Resulte in the enrichment of bifidobacteria and a reduction in the levels of Bacteroidetes;might protect against the adverse effects of chemotherapy	PMID: 28270698
Bifidobacterium	Polysaccharides (after cyclophosphamide administration)	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	Resulte in the enrichment of bifidobacteria and a reduction in the levels of Bacteroidetes;might protect against the adverse effects of chemotherapy	PMID: 28270698
Bacteroides fragilis	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	(E)-5-(2-bromovinyl) uracil (BVU)	n.a.	n.a.	n.a.	Gut bacterial phosphorolytic enzyme	[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients	PMID: 28270698
Bacteroides thetaiotaomicron	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	(E)-5-(2-bromovinyl) uracil (BVU)	n.a.	n.a.	n.a.	Gut bacterial phosphorolytic enzyme	[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients	PMID: 28270698
Bacteroides uniformis	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	(E)-5-(2-bromovinyl) uracil (BVU)	n.a.	n.a.	n.a.	Gut bacterial phosphorolytic enzyme	[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients	PMID: 28270698
Bacteroides vulgatus	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	(E)-5-(2-bromovinyl) uracil (BVU)	n.a.	n.a.	n.a.	Gut bacterial phosphorolytic enzyme	[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients	PMID: 28270698
Bacteroides eggerthii	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	(E)-5-(2-bromovinyl) uracil (BVU)	n.a.	n.a.	n.a.	Gut bacterial phosphorolytic enzyme	[drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients	PMID: 28270698
Unidentified gut microbes	Neoprontosil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Microbiota-driven drug metabolism	Affect drug disposition and toxicity	PMID: 28270698
Unidentified gut microbes	Sulfanilamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Microbiota-driven drug metabolism	Affect drug disposition and toxicity	PMID: 28270698
Bacteroides thetaiotaomicron	Brivudine	Therapeutic Substance	Approved Drug	n.a.	bromovinyluracil (BVU)	Increase Toxicity	Mouse	Conventional(CV),germ-free(GF)	Microbial enzymes	Conversion to hepatotoxic BVU;(GF)reduce systemic BVU exposure	PMID: 30733391
Bacteroides ovatus	Brivudine	Therapeutic Substance	Approved Drug	n.a.	bromovinyluracil (BVU)	Increase Toxicity	n.a.	n.a.	n.a.	Conversion to hepatotoxic BVU;(GF)reduce systemic BVU exposure	PMID: 30733391
Unidentified gut microbes	Clonazepam	Therapeutic Substance	Approved Drug	n.a.	aminoclonazepam (NH2-CLZ),aminohydroxyclonazepam (NH2OH-CLZ)	Increase Toxicity	Mouse	Conventional(CV),germ-free(GF)	Contribute to the reductive metabolism of CLZ	Lead to toxicity	PMID: 30733391
Bacteroides thetaiotaomicron	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	bromovinyluracil (BVU)	Increase Toxicity	Mouse	Conventional(CV),germ-free(GF)	Microbial enzymes	Metabolized by members of this genus	PMID: 30733391
Bacteroides ovatus	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	bromovinyluracil (BVU)	Increase Toxicity	n.a.	n.a.	n.a.	Metabolized by members of this genus	PMID: 30733391
Unidentified gut microbes	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	2-hydroxy lovastatic acid,2-hydroxy simvastatin acid	Increase Efficacy	Rat	n.a.	n.a.	Product an active form;drug interaction:antibiotics suppresses the pharmacologic effects	PMID: 9728898; PMID: 24947972; PMID: 25926432; PMID: 25571290
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	2-hydroxy lovastatic acid,2-hydroxy simvastatin acid	Increase Efficacy	Rat	n.a.	n.a.	Product an active form;drug interaction:antibiotics suppresses the pharmacologic effects	PMID: 9728898; PMID: 24947972; PMID: 25926432; PMID: 25571290
Clostridium perfringens	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	N-(2-hydroxyethyl)-oxamic acid and acetamide	n.a.	Rat	n.a.	Reduced metabolites	n.a.	PMID: 231450; PMID: 430360; PMID: 25926432
Streptococcus pyogenes	Sulfanilamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	sulfanilamide	Increase Efficacy	Mouse	A murine model of Streptococcus pyogenes systemic infection	The gut microbiota transformed drug by azoreductases	Exhibit potent antibacterial activity;drug interaction:antibiotics suppresses the conversion	PMID: 4405598; Peppercorn and Goldman,1976; PMID: 25926432
Unidentified gut microbes	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	calycosin	n.a.	n.a.	n.a.	Aromatic hydroxylase and O-methyltransferase	Drug interaction:antibiotics suppresses the transformation	PMID: 9657051; PMID: 25926432; PMID: 9781846
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	Increase Toxicity	n.a.	n.a.	The b-glucuronidases of the gut microbiota	Causes diarrhea;drug interaction:coadministration of the poorly absorbed aminoglycoside antibiotic neomycin could be advantageous for diarrhea	PMID: 25926432; PMID: 11350876
Unidentified gut microbes	Sulindac sulfide	Environmental Chemicals	Active Metabolite of Prodrug	n.a.	n.a.	n.a.	Human	Healthy,ileostomy	n.a.	Drug interaction:metronidazole decreases the formation of sulfides of sulindac ex vivo	PMID: 3630204; PMID: 25926432
Unidentified gut microbes	Neoprontosil	Therapeutic Substance	Approved Drug	n.a.	sulfanilamide	Increase Efficacy	Rat	n.a.	n.a.	Product the pharmacologically active metabolite;drug interaction:antibiotics reduced the amount of sulfanilamide excreted in the urine after oral administration	PMID: 5173017; PMID: 25926432
Unidentified gut microbes	Misonidazole	Therapeutic Substance	Investigational Drug	n.a.	1-(2-aminoimidazol-1-yl)-3-methoxypropan-2-ol	Increase Toxicity	Rat	Convention,germ-free	n.a.	Drug interaction:antibiotic inhibits misonidazole transformation and toxicity	PMID: 6260109; PMID: 25926432
Unidentified gut microbes	Clonazepam	Therapeutic Substance	Approved Drug	n.a.	7-aminoclonazepam	n.a.	Rat	Germ-free and ex–germ-free	The reductive metabolism	Drug interaction:antibiotic suppresses the reduction	PMID: 6506755; PMID: 25926432
Unidentified gut microbes	Loperamide oxide	Therapeutic Substance	Investigational Drug	n.a.	loperamide	n.a.	Rat; Dog	n.a.	Microbiota is involved in reduction	Drug interaction:absorption of orally delivered loperamide oxide is lower when administered with cotrimoxazole	PMID: 25926432; PMID: 8838438
Unidentified gut microbes	Daidzin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	daidzein,calycosin	Increase Efficacy	n.a.	n.a.	C-glucosidases and O-glucosidases	Drug interaction:Antibiotic inhibits the metabolism of isoflavone glycosides	PMID: 9657051; PMID: 25926432
Unidentified gut microbes	Puerarin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	daidzein,calycosin	Increase Efficacy	n.a.	n.a.	C-glucosidases and O-glucosidases	Drug interaction:Antibiotic inhibits the metabolism of isoflavone glycosides	PMID: 9657051; PMID: 25926432
Unidentified gut microbes	Fenfluramine	Therapeutic Substance	Approved Drug	n.a.	phenolic acids	n.a.	Human; Mouse	n.a.	Deglycosylating enzymes of bacteria	Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats	PMID: 25926432; PMID: 9875509
Unidentified gut microbes	Hesperidin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	phenolic acids	n.a.	Human; Mouse	n.a.	Deglycosylating enzymes of bacteria	Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats	PMID: 25926432; PMID: 9875509
Unidentified gut microbes	Naringenin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	phenolic acids	n.a.	Human; Mouse	n.a.	Deglycosylating enzymes of bacteria	Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats	PMID: 25926432; PMID: 9875509
Unidentified gut microbes	Rutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	phenolic acids	n.a.	Human; Mouse	n.a.	Deglycosylating enzymes of bacteria	Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats	PMID: 25926432; PMID: 9875509
Unidentified gut microbes	Scutellaria baicalensis root	Therapeutic Substance	Investigational Drug	n.a.	phenolic acids	n.a.	Human; Mouse	n.a.	Deglycosylating enzymes of bacteria	Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats	PMID: 25926432; PMID: 9875509
Unidentified gut microbes	Wognoside	Herbal Substance	Medicinal Herbal Compounds	n.a.	phenolic acids	n.a.	Human; Mouse	n.a.	Deglycosylating enzymes of bacteria	Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats	PMID: 25926432; PMID: 9875509
Unidentified gut microbes	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	dihydrodigoxin,dihydrodigoxigenin	Decrease Efficacy	Human	n.a.	n.a.	Convert to the inactive metabolites;attenuates the drug’s effects;drug interaction:antibiotics（erythromycin and tetracycline）blocks the reduction of digoxin	PMID: 25926432; PMID:7266632
Unidentified gut microbes	Sulindac	Therapeutic Substance	Approved Drug	n.a.	sulindac sulfide	n.a.	Rabbit	n.a.	n.a.	n.a.	PMID: 25926432
Unidentified gut microbes	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Transform drugs and phytochemicals into bioinactive metabolites	Affect the pharmacokinetics	PMID: 25926432
Lactococcus garvieae	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	5-hydroxy-equol	n.a.	Human; Animal models	n.a.	n.a.	n.a.	PMID: 25926432
Adlercreutzia equolifaciens	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	5-hydroxy-equol	n.a.	Human; Animal models	n.a.	n.a.	n.a.	PMID: 25926432
Slackia equolifaciens	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	5-hydroxy-equol	n.a.	Human; Animal models	n.a.	n.a.	n.a.	PMID: 25926432
Slackia isoflavoniconvertens	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	5-hydroxy-equol	n.a.	Human; Animal models	n.a.	n.a.	n.a.	PMID: 25926432
Lactococcus garvieae	Genistein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	5-hydroxy-equol	n.a.	Human; Animal models	n.a.	n.a.	n.a.	PMID: 25926432
Adlercreutzia equolifaciens	Genistein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	5-hydroxy-equol	n.a.	Human; Animal models	n.a.	n.a.	n.a.	PMID: 25926432
Slackia equolifaciens	Genistein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	5-hydroxy-equol	n.a.	Human; Animal models	n.a.	n.a.	n.a.	PMID: 25926432
Slackia isoflavoniconvertens	Genistein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	5-hydroxy-equol	n.a.	Human; Animal models	n.a.	n.a.	n.a.	PMID: 25926432
Ruminococcus sp.	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K)	Increase Efficacy	n.a.	n.a.	n.a.	Drug interaction:antibiotics inhibits the metabolism	PMID: 25926432
Oscillibacter sp.	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K)	Increase Efficacy	n.a.	n.a.	n.a.	Drug interaction:antibiotics inhibits the metabolism	PMID: 25926432
Sutterella sp.	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K)	Increase Efficacy	n.a.	n.a.	n.a.	Drug interaction:antibiotics inhibits the metabolism	PMID: 25926432
Holdemania sp.	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K)	Increase Efficacy	n.a.	n.a.	n.a.	Drug interaction:antibiotics inhibits the metabolism	PMID: 25926432
Unidentified gut microbes	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Efficacy	n.a.	n.a.	Transform drugs and phytochemicals into bioactive metabolites	Affect the pharmacokinetics	PMID: 25926432
Bacteroides	Lactulose	Therapeutic Substance	Approved Drug	n.a.	fructose,galactose	n.a.	n.a.	n.a.	n.a.	Drug interaction:combination treatment with neomycin and lactulose reduces the blood ammonia concentration in pigs	PMID: 25926432
Lactobacillus	Lactulose	Therapeutic Substance	Approved Drug	n.a.	fructose,galactose	n.a.	n.a.	n.a.	n.a.	Drug interaction:combination treatment with neomycin and lactulose reduces the blood ammonia concentration in pigs	PMID: 25926432
Escherichia coli	Lactulose	Therapeutic Substance	Approved Drug	n.a.	fructose,galactose	n.a.	n.a.	n.a.	n.a.	Drug interaction:combination treatment with neomycin and lactulose reduces the blood ammonia concentration in pigs	PMID: 25926432
Clostridium sp.	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	levametabol-I, levametabol-II, and levametabol-III	n.a.	n.a.	n.a.	n.a.	Drug interaction: Combined therapy with tetracycline and levamisole has a stronger biologic effect	PMID: 25926432
Bacteroides spp.	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	levametabol-I, levametabol-II, and levametabol-III	n.a.	n.a.	n.a.	n.a.	Drug interaction: Combined therapy with tetracycline and levamisole has a stronger biologic effect	PMID: 25926432
Unidentified gut microbes	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Efficacy	n.a.	n.a.	Transform drugs and phytochemicals into bioactive metabolites	Affect the pharmacokinetics	PMID: 25926432
Unidentified gut microbes	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Transform drugs and phytochemicals into bioinactive metabolites	Affect the pharmacokinetics	PMID: 25926432
[Eubacterium] rectale	Picosulfuric acid	Therapeutic Substance	Approved Drug	n.a.	free diphenol[4,49-(pyridin-2-ylmethanediyl)diphenol]	Increase Efficacy	n.a.	n.a.	Arylsulfate sulfotransferase of bacteria	Have a laxative effect;drug interaction:antibiotics inhibits the transformation	PMID: 25926432
Unidentified gut microbes	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Transform drugs and phytochemicals into bioinactive metabolites	Affect the pharmacokinetics	PMID: 25926432
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid	Increase Efficacy	n.a.	n.a.	Azoreductases produced by metabolize	Induces anti-inflammatory effects	PMID: 25926432
Unidentified gut microbes	Epicatechin	Therapeutic Substance	Investigational Drug	n.a.	phenolic acids	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 25926432
Unidentified gut microbes	Anthocyanidins	Herbal Substance	Plant Compounds	n.a.	phenolic acids	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 25926432
Unidentified gut microbes	Balsalazide	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid	n.a.	Human	n.a.	n.a.	Drug interaction:antibiotic suppresses the metabolism,limit its effectiveness	PMID: 25926432
Unidentified gut microbes	Cianidanol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	phenolic acids	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 25926432
Unidentified gut microbes	Flucytosine	Therapeutic Substance	Approved Drug	n.a.	5-fluorouracil	n.a.	n.a.	n.a.	n.a.	Drug interaction:antimicrobial agents may reduce the antifungal effect of flucytosine	PMID: 25926432
Unidentified gut microbes	Glycyrrhizic acid	Therapeutic Substance	Approved Drug	n.a.	18b-glycyrrhetic acid	n.a.	Rat	Germ-free	n.a.	Drug interaction:antibiotics(amoxicillin and metronidazole)suppresses the conversion	PMID: 25926432
Unidentified gut microbes	Hesperidin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	hesperetin	n.a.	Rat	n.a.	n.a.	Suppress gut bacterial glycosidase activities;drug interaction:Antibiotic inhibits the metabolism	PMID: 25926432
Unidentified gut microbes	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	tyramine,m-hydroxyphenylacetic acid	n.a.	n.a.	n.a.	n.a.	Drug interaction:antibiotics(vancomycin)inhibits the dehydroxylation of bile acid by the gut microbiota	PMID: 25926432
Unidentified gut microbes	Nitrazepam	Therapeutic Substance	Approved Drug	n.a.	7-amino-nitrazepam	Increase Toxicity	Rat	n.a.	Transform drugs and phytochemicals into toxic metabolites	Affect the pharmacokinetics,product an active teratogenic substance;drug interaction: antibiotic reduced nitrazepam-induced teratogenicity	PMID: 25926432
Unidentified gut microbes	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	hydroxyiminonizatidine	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 25926432
Unidentified gut microbes	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	hydroxyiminoranitidine	n.a.	n.a.	n.a.	n.a.	Drug interaction:antibiotics(rifampicin)decreases the absorption of ranitidine	PMID: 25926432
Unidentified gut microbes	Risperidone	Therapeutic Substance	Approved Drug	n.a.	dihydroxy-risperidone,hydroxy-keto-risperidone	n.a.	Rat	n.a.	Scission of isoxazole	Drug interaction:Antibiotics(rifampin)inhibit the bioavailability of risperidone in the liver	PMID: 25926432
Unidentified gut microbes	Scutellaria baicalensis root	Therapeutic Substance	Investigational Drug	n.a.	oroxylin A	n.a.	n.a.	n.a.	Aromatic hydroxylase and O-methyltransferase	n.a.	PMID: 25926432
Unidentified gut microbes	Sennosides	Therapeutic Substance	Investigational Drug	n.a.	rheinanthrone	Increase Efficacy	n.a.	n.a.	Reductase(s) and 3- b-D-glucosidase(s)	Product a purgative compound;drug interaction:antibiotics（chloramphenicol, streptomycin, and rifampicin）inhibits the biotransformation	PMID: 25926432
Unidentified gut microbes	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	sulfinpyrazone sulfide	n.a.	Rabbit	n.a.	n.a.	Drug interaction:Metronidazole decreases the extent of sulfinpyrazone reduction in rabbits in vivo	PMID: 25926432
Unidentified gut microbes	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	2-sulfamoyacetylphenol	n.a.	n.a.	n.a.	Through the reduction	n.a.	PMID: 25926432
Unidentified gut microbes	Hydrazine	Environmental Chemicals	Industrial Chemicals; Medicinal chemicals	n.a.	n.a.	Decrease Toxicity	Rat	n.a.	DszA/NtaA-like oxygenase	n.a.	PMID: 19396371; PMID: 26261284
Unidentified anaerobic bacterium	Fostamatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	O-demethylation and dihydroxylation by bacteria	n.a.	PMID: 26261284; PMID: 20371637
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Reactivated by bacterially expressed b-glucuronidase	Result in diarrhea	PMID: 26261284; PMID: 21051639
Unidentified gut microbes	BILR355	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Bacterially mediated N-oxide reduction	Drug interaction:(with ritonavir)bacterial mediated reactions predominate	PMID: 26261284; PMID: 22393121
Unidentified gut microbes	2-chloro-5-nitro-N-phenylbenzamide	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Bacterial nitroreductases	Alter its mutagenicity	PMID: 26261284; PMID: 22450444
Unidentified gut microbes	Antiobiotics	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug interaction:antibiotics effect the functional activity of bacteria	PMID: 26261284; PMID: 23332745
Unidentified gut microbes	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug interaction:antibiotics effect the functional activity of bacteria	PMID: 26261284; PMID: 23332745
Unidentified gut microbes	Phenacetin	Therapeutic Substance	Approved Drug (Withdrawn)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug interaction:antibiotics effect the functional activity of bacteria	PMID: 26261284; PMID: 23332745
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug interaction:antibiotics effect the functional activity of bacteria	PMID: 26261284; PMID: 23332745
Sulfite-reducing bacterium LF11mE1	Saturated fats	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Excess consumption of fat leads to an increase in the growth of bacteria	Increase the formation of proinflammatory and genotoxic secondary bile acids(deoxycholate)	PMID: 26261284; PMID: 24355793
Clostridioides difficile	Saturated fats	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Excess consumption of fat leads to an increase in the growth of bacteria	Increase the formation of proinflammatory and genotoxic secondary bile acids(deoxycholate)	PMID: 26261284; PMID: 24355793
Unidentified gut microbes	Arsenic	Environmental Chemicals	Toxic Agents	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	Alter the gut microbiota	PMID: 26261284; PMID: 24413286
Unidentified gut microbes	Phenoxyethanol	Therapeutic Substance	Approved Drug	n.a.	cyanuric acid	Increase Toxicity	n.a.	n.a.	Microbial formation of its metabolite	Lead to toxicity	PMID: 26261284; PMID: 25105361
Faecalibacterium prausnitzii	Tacrolimus	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Alter the pharmacokinetics of tacrolimus	PMID: 26261284; PMID: 25815766
Unidentified gut microbes	Astragali radix	Herbal Substance	Medicinal Herb	n.a.	n.a.	n.a.	Rat	n.a.	Calycosin-7-O-b-D-glucoside may alter the composition of the gut microbiome	Promot the growth of beneficial organisms(Lactobacillus and Bifidobacterium)	PMID: 26261284; PMID: 26101224
Unidentified gut microbes	Calycosin-7-O-b-D-glucoside	Herbal Substance	Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Rat	n.a.	Calycosin-7-O-b-D-glucoside may alter the composition of the gut microbiome	Promot the growth of beneficial organisms(Lactobacillus and Bifidobacterium)	PMID: 26261284; PMID: 26101224
Unidentified gut microbes	Epimedium grandiflorum top (flavonoids)	Herbal Substance	Medicinal Herb	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolized by the colonic microflora to circulate in the plasma	[disease]osteoporosis may modulate the metabolism of Epimedii and may affect its bioavailability and efficacy	PMID: 26135008; PMID: 26261284
Unidentified gut microbes	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Microbial (p-cresol) may compete for a host enzyme (SULT1A1)	PMID: 26261284
Desulfovibrio desulfuricans	Arsenic	Environmental Chemicals	Toxic Agents	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Sulfate-reducing bacteria	Product a more toxic form of arsenic	PMID: 26261284
Firmicutes	Butyric Acid	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Produce relatively high levels of butyrate in the gastrointestinal tract	Limit the growth of pathogenic microorganisms	PMID: 26261284
Faecalibacterium prausnitzii	Butyric Acid	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Produce relatively high levels of butyrate in the gastrointestinal tract	Limit the growth of pathogenic microorganisms	PMID: 26261284
Escherichia coli	Curcumin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	tetrahydrocurcumin	Increase Efficacy	n.a.	n.a.	Enzyme(identified as CurA)	n.a.	PMID: 26261284
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Cardiac glycoside expressed by bacteria	Drug is inactivated	PMID: 26261284
Helicobacter pylori	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Sequestration of bacteria	Reactivated by microbially expressed enzymes	PMID: 26261284
Escherichia coli	Nitrobenzodiazepine	Therapeutic Substance	Drug Class	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Bacterial nitroreductase(NfsB)	n.a.	PMID: 26261284
Micrococcus luteus	Polyaromatic compounds	Environmental Chemicals	Unclassified Substance	n.a.	hydroxyl metabolites	n.a.	n.a.	n.a.	n.a.	Exhibit estrogenic activities	PMID: 26261284
Clostridioides difficile	PPIs	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug is associated with Clostridium difficule infections	PMID: 26261284
Unidentified gut microbes	Resveratrol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Enzyme(identified as CurA)	n.a.	PMID: 26261284
Enterobacter	Tretazicar	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA))	n.a.	PMID: 26261284
Staphylococcus	Tretazicar	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA))	n.a.	PMID: 26261284
Escherichia coli	Tretazicar	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA))	n.a.	PMID: 26261284
Mycobacterium	Tretazicar	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA))	n.a.	PMID: 26261284
Bacillus	Tretazicar	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA))	n.a.	PMID: 26261284
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Be extensively metabolized by microbiota(demethylation, carbon-carbon bond cleavage, a or b oxidation,dihydroxylation, and cyclization of simvastatin)	n.a.	PMID: 26261284
Unidentified gut microbes	Sulfadiazine	Therapeutic Substance	Approved Drug	n.a.	5-amino 5-salicylic acid	Increase Efficacy	n.a.	n.a.	Convert drug to its pharmacologically active form by microbial enzymes	n.a.	PMID: 26261284
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	Increase Toxicity	n.a.	n.a.	Convertion to SN-38	Lead to the severe intestinal side effect of diarrhea;[drug interaction:Antibiotic/a potent inhibitor of β-glucuronidase can reduce intestinal side effect]	PMID: 26569070; PMID: 18927500
Unidentified gut microbes	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	High level of a microbial metabolite(p-cresol)	Show low postdose acetaminophen sulfate to acetaminophen glucuronide;alter the bioavailability;lead to hepatotoxicity;[drug interaction]:(rat)antibiotic lead to higher level of acetaminophen glutathione conjugates	PMID: 26569070; PMID: 19667173
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Several gut microbial-derived secondary bile acids	Secondary bile acids can predict effect of simvastatin	PMID: 26569070; PMID: 24947972
Firmicutes	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Alter the composition of gut microbiota;induce the translocation(Gram positive bacteria)into secondary lymphoid organs	PMID: 26569070
Unidentified anaerobic bacterium	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	sulfide metabolites	Decrease Efficacy	n.a.	n.a.	Reduction	Decreased activity	PMID: 26569070
Clostridioides difficile	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	Acetaminophen sulfate and glucuronide	Decrease Efficacy; Increase Toxicity	n.a.	n.a.	O-Sulfation; C-S cleavage of acetaminophen-3-cysteine	Decrease activity,or increase cellular toxicity	PMID: 26569070
Unidentified gut microbes	CpG-oligonucleotide immunotherapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Mouse	Germ free,orantibiotic-treated	Disruption of gut microbiota	Microbiota impairs the therapeutic responses of tumors	PMID: 26569070
Unidentified anaerobic bacterium	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Dihydrodaidzein, equol, or O-desmethylanolensin(ODMA)	Increase Efficacy	n.a.	n.a.	Reduction, phenolic ring opening	Increased activity	PMID: 26569070
Clostridium sp. HGH 136	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Dihydrodaidzein, equol, or O-desmethylanolensin(ODMA)	Increase Efficacy	n.a.	n.a.	Reduction, phenolic ring opening	Increased activity	PMID: 26569070
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	dihydrodigoxin	Decrease Efficacy	n.a.	n.a.	Key enzyme: A cytochrome-encoding operon (termed the cardiac glycoside reductase)	Produce inactive metabolite	PMID: 26569070
Bacteroides uniformis	Genistein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	5-hydroxyequol	n.a.	n.a.	n.a.	Hydrogenation	n.a.	PMID: 26569070
Bacteroides	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Compound K	Increase Efficacy	n.a.	n.a.	Hydrolysis	Increased activity	PMID: 26569070
Bifidobacterium	Ginsenoside Rb1	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Compound K	Increase Efficacy	n.a.	n.a.	Hydrolysis	Increased activity	PMID: 26569070
Eubacterium sp. GLH	Glycyrrhizic acid	Therapeutic Substance	Approved Drug	n.a.	18-β-glycyrrhetinic acid	Increase Efficacy	n.a.	n.a.	Hydrolysis	Increased activity	PMID: 26569070
Klebsiella pneumoniae	Lactulose	Therapeutic Substance	Approved Drug	n.a.	Monosaccharides	n.a.	n.a.	n.a.	Hydrolysis	Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli)	PMID: 26569070
Enterococcus faecalis	Lactulose	Therapeutic Substance	Approved Drug	n.a.	Monosaccharides	n.a.	n.a.	n.a.	Hydrolysis	Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli)	PMID: 26569070
Cronobacter sakazakii	Lactulose	Therapeutic Substance	Approved Drug	n.a.	Monosaccharides	n.a.	n.a.	n.a.	Hydrolysis	Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli)	PMID: 26569070
Enterococcus casseliflavus	Lactulose	Therapeutic Substance	Approved Drug	n.a.	Monosaccharides	n.a.	n.a.	n.a.	Hydrolysis	Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli)	PMID: 26569070
Bacteroides	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	levametabol-I, II and III	Increase Efficacy	n.a.	n.a.	Thiazole ring opening	Increased activity	PMID: 26569070
Clostridium sp.	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	levametabol-I, II and III	Increase Efficacy	n.a.	n.a.	Thiazole ring opening	Increased activity	PMID: 26569070
Clostridia	Metamfetamine	Therapeutic Substance	Approved Drug	n.a.	Amphetamine, norephedrine and an unknown metabolite	Decrease Efficacy	n.a.	n.a.	Demethylation	Decreased activity	PMID: 26569070
Enterococcus	Metamfetamine	Therapeutic Substance	Approved Drug	n.a.	Amphetamine, norephedrine and an unknown metabolite	Decrease Efficacy	n.a.	n.a.	Demethylation	Decreased activity	PMID: 26569070
Lactobacillus	Metamfetamine	Therapeutic Substance	Approved Drug	n.a.	Amphetamine, norephedrine and an unknown metabolite	Decrease Efficacy	n.a.	n.a.	Demethylation	Decreased activity	PMID: 26569070
Unidentified gut microbes	Platinum chemotherapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Mouse	Germ free,orantibiotic-treated	Disruption of gut microbiota	Microbiota impairs the therapeutic responses of tumors	PMID: 26569070
Enterococcus casseliflavus	Quercetin-3-glucoside	Herbal Substance; Dietary Substance	Medicinal Herbal Compounds; Dietary Compounds	n.a.	Butyrate, acetate, 3,4-dihydroxyphenylacetic acid	n.a.	n.a.	n.a.	Deglycosylation	n.a.	PMID: 26569070
Eubacterium ramulus	Quercetin-3-glucoside	Herbal Substance; Dietary Substance	Medicinal Herbal Compounds; Dietary Compounds	n.a.	Butyrate, acetate, 3,4-dihydroxyphenylacetic acid	n.a.	n.a.	n.a.	Deglycosylation	n.a.	PMID: 26569070
Escherichia coli	Diclofenac	Therapeutic Substance	Approved Drug	Hydrolysis to diclofenac	Diclofenac glucuronide	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 24780296; PMID: 22328575
Escherichia coli	Flucytosine	Therapeutic Substance	Approved Drug	Deamination	5-fluorouracil	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 12714804; PMID: 3729334
Unidentified anaerobic bacterium	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Double bond reduction	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 6836275; PMID: 24637603; PMID: 27591027; PMID: 1500644; PMID: 2759492
Clostridioides difficile	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Double bond reduction	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 6836275; PMID: 24637603; PMID: 27591027; PMID: 1500644; PMID: 2759492
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Double bond reduction	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 6836275; PMID: 24637603; PMID: 27591027; PMID: 1500644; PMID: 2759492
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Double bond reduction	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 6836275; PMID: 24637603; PMID: 27591027; PMID: 1500644; PMID: 2759492
Unidentified gut microbes	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Pseudomonas aeruginosa	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Citrobacter freundii	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Klebsiella oxytoca	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Klebsiella pneumoniae subsp. ozaenae	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Morganella morganii	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Serratia marcescens	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Shigella flexneri	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Vibrio cholerae	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Plesiomonas shigelloides	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Citrobacter amalonaticus	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Klebsiella pneumoniae subsp. rhinoscleromatis	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Citrobacter farmeri	Mesalazine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl-5-aminosalicylic acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356
Clostridium sporogenes	Zonisamide	Therapeutic Substance	Approved Drug	Benzisoxazole ring reduction	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 9231340; PMID: 1615700
Unidentified gut microbes	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	N-oxide reduction	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 11564550
Unidentified gut microbes	Nizatidine	Therapeutic Substance	Approved Drug	N-oxide reduction	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 11955801
Bacteroides	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Thiazole ring opening	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 1949905
Clostridium sp.	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Thiazole ring opening	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 1949905
Unidentified anaerobic bacterium	Fostamatinib	Therapeutic Substance	Approved Drug	O-Demethylation	metabolite R529	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 20371637
Unidentified gut microbes	Sulfapyridine	Therapeutic Substance	Approved Drug	Acetylation	N-acetyl sulfapyridine	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 2890356
Unidentified anaerobic bacterium	Sulfinpyrazone	Therapeutic Substance	Approved Drug	Sulfoxide reduction	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 3630204
Unidentified anaerobic bacterium	Sulindac	Therapeutic Substance	Approved Drug	Sulfoxide reduction	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 27591027; PMID: 3630204
Escherichia coli	Irinotecan	Therapeutic Substance	Approved Drug	Glucuronide hydrolysis	SN-38 glucuronide	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027
Bacteroides fragilis	Irinotecan	Therapeutic Substance	Approved Drug	Glucuronide hydrolysis	SN-38 glucuronide	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027
Streptococcus agalactiae	Irinotecan	Therapeutic Substance	Approved Drug	Glucuronide hydrolysis	SN-38 glucuronide	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027
Clostridium perfringens	Irinotecan	Therapeutic Substance	Approved Drug	Glucuronide hydrolysis	SN-38 glucuronide	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027
Unidentified gut microbes	3,4-Dihydro-5-Methyl-Isoquinolinone	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	Mouse	Convention and germ-free	n.a.	DHQ production was dependent on bacteria	PMID: 27782392; PMID: 19234110
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug modulate or interact with the microbiota	PMID: 21060933; PMID: 27782392
Unidentified gut microbes	Hippuric acid	Environmental Chemicals	Industrial Chemicals and Pollutants; Toxic Agents	n.a.	n.a.	Increase Efficacy	Mouse	Germ-free,or with antibiotics	n.a.	Drug concentration in urine is reduced in either germ-free mice or in mice treated with antibiotics	PMID: 27782392; PMID: 23342949
Unidentified gut microbes	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	n.a.	Increase hat fatty acid metabolism	Contribute to metformin therapy	PMID: 25038099; PMID: 27782392
Unidentified gut microbes	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug modulate or interact with the microbiota	PMID: 25038099; PMID: 27782392
Unidentified gut microbes	Levocarnitine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	TMA, TMAO	n.a.	n.a.	n.a.	L-carnitine is metabolized to TMA by microbiota	Decrease AGE levels	PMID: 25636076; PMID: 27782392
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Β-glucuronidase enzyme of bacteria	Cause gut inflammation and irritation;drug interaction:irinotecan with a β-glucuronidase inhibitor decreases harmful metabolites and alleviates the gastrointestinal inflammation	PMID: 27782392; PMID: 26364932
Unidentified gut microbes	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	m-tyramine	n.a.	Mouse	Germ-free	n.a.	(GF mice)reduce metabolism of L-DOPA,prolong L-DOPA half-life and hence activity	PMID: 4974346; PMID: 27782392
Escherichia sp.	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Cause an increase of Escherichia spp	Result in an increase of gas metabolism pathways(side effect of metformin)	PMID: 27782392
Pseudomonas aeruginosa	2,8-DHQ (including 2,4-DHQ)	Environmental Chemicals	Human Metabolite	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	n.a.	Drug is involved in the pathogenicity of bacteria	PMID: 27782392
Enterobacteriaceae	Aspartame	Therapeutic Substance; Dietary Substance; Herbal Substance	Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds	n.a.	SCFA(propionate)	n.a.	Rat	n.a.	n.a.	Aspartame increased total bacteria	PMID: 27782392
[Clostridium] leptum	Aspartame	Therapeutic Substance; Dietary Substance; Herbal Substance	Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds	n.a.	SCFA(propionate)	n.a.	Rat	n.a.	n.a.	Aspartame increased total bacteria	PMID: 27782392
Bifidobacterium	B-GOSr (prebiotic oligosaccharide)	Therapeutic Substance	n.a.	n.a.	SCFA(acetate)	n.a.	Human	n.a.	n.a.	Bacteria populations increases acetate	PMID: 27782392
Clostridia	Choline	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	trimethylamine (TMA)	n.a.	n.a.	n.a.	n.a.	Have a direct relationship to cardiovascular disease and atherosclerosis	PMID: 27782392
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	dihydrodigoxin	Decrease Efficacy	n.a.	n.a.	The cgr operon within strains of E. lenta reduce fumarate in E. lenta to reduce digoxin	Lack cardiac activity	PMID: 27782392
Bacteroides	Lactulose	Therapeutic Substance	Approved Drug	n.a.	lactic acid,acetic acid	Increase Efficacy	n.a.	n.a.	n.a.	Produce its therapeutic metabolites	PMID: 27782392
Bifidobacterium	Lactulose	Therapeutic Substance	Approved Drug	n.a.	lactic acid,acetic acid	Increase Efficacy	n.a.	n.a.	n.a.	Produce its therapeutic metabolites	PMID: 27782392
Clostridia	Sodium cyclamate	Dietary Substance	Dietary Compounds; Artificial Sweetener	n.a.	cyclohexylamine	n.a.	Human; Mouse	n.a.	n.a.	Drug interaction:antibiotic treatment reduce cyclohexylamine production	PMID: 27782392
Enterococcus	Sodium cyclamate	Dietary Substance	Dietary Compounds; Artificial Sweetener	n.a.	cyclohexylamine	n.a.	Human; Mouse	n.a.	n.a.	Drug interaction:antibiotic treatment reduce cyclohexylamine production	PMID: 27782392
Unidentified gut microbes	3,3-dimethyl-1-butanol	Environmental Chemicals	Unclassified Substance	n.a.	TMA, TMAO	n.a.	Mouse	n.a.	n.a.	Drug interaction:inhibition of TMA lyase inhibits microbial production of TMA, reducing TMAO levels	PMID: 27782392
Unidentified gut microbes	Arabinoxylan-oligosaccharides	Environmental Chemicals	Unclassified Substance	n.a.	SCFA; phenol, pcresol	n.a.	Human	n.a.	n.a.	AXOS supplementation has a long-term effect on colonic microbe community	PMID: 27782392
Unidentified gut microbes	Aryl hydrocarbon receptor activator	Environmental Chemicals	Industrial Chemicals and Pollutants; Toxic Agents	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Alter the gut microbiota community its metabolic function	PMID: 27782392
Unidentified gut microbes	Ellagic acid	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Alter the gut microbiota community its metabolic function	PMID: 27782392
Unidentified gut microbes	Arsenic	Environmental Chemicals	Toxic Agents	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Alter the gut microbiota community its metabolic function	PMID: 27782392
Escherichia coli	NSAIDs	Therapeutic Substance	Drug Class	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Cleave the glucuronide by bacteria	Yield harmful metabolites,cause the formation of ulcers in the gut;	PMID: 27782392
Unidentified gut microbes	Persistent organic pollutant	Environmental Chemicals	Industrial Chemicals and Pollutants	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Alter the gut microbiota community its metabolic function	PMID: 27782392
Unidentified gut microbes	Rifaximin	Therapeutic Substance	Approved Drug	n.a.	Hippuric acid	n.a.	Mouse	n.a.	n.a.	Drug interaction:antibiotic(rifaximin)decreases microbial metabolites(hippuric acid)	PMID: 27782392
Lactobacillus	Tempol	Therapeutic Substance	Investigational Drug	n.a.	TβMCA	n.a.	Mouse	n.a.	n.a.	Tempol reduces BSH activity of bacteria and produces antiobesity effects	PMID: 27782392
Unidentified gut microbes	Oxaliplatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Immunomodulation	Mediated by TLR4 and reactive oxygen species production by myeloid cells	PMID: 18555978; PMID: 28270698
Mycoplasma	Floxuridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Enzymatic degradation	Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity	PMID: 28270698
Mycoplasma	Trifluridine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Enzymatic degradation	Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity	PMID: 28270698
Bifidobacterium	Anti-PD-L1 therapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Immunomodulation	Tumour‑specific T‑cell induction;increase T cells in tumour microenvironment	PMID: 28270698
Proteobacteria	Carmustine, Etoposide, Cytarabine and melphalan combination	Therapeutic Substance	Drug Combination	n.a.	n.a.	n.a.	n.a.	n.a.	Reduced diversity; ecological network function	Chemotherapy associated with reduction in bacteria that limit inflammation and increase in bacteria associated with colitis	PMID: 28270698
Firmicutes	Carmustine, Etoposide, Cytarabine and melphalan combination	Therapeutic Substance	Drug Combination	n.a.	n.a.	n.a.	n.a.	n.a.	Reduced diversity; ecological network function	Chemotherapy associated with reduction in bacteria that limit inflammation and increase in bacteria associated with colitis	PMID: 28270698
Actinobacteria	Carmustine, Etoposide, Cytarabine and melphalan combination	Therapeutic Substance	Drug Combination	n.a.	n.a.	n.a.	n.a.	n.a.	Reduced diversity; ecological network function	Chemotherapy associated with reduction in bacteria that limit inflammation and increase in bacteria associated with colitis	PMID: 28270698
Ruminococcus	CpG oligodeoxynucleotides	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Immunomodulation	Priming of tumour‑associated myeloid inflammatory responses	PMID: 28270698
Alistipes	CpG oligodeoxynucleotides	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Immunomodulation	Priming of tumour‑associated myeloid inflammatory responses	PMID: 28270698
Bacteroidales	CTLA-4 blockade	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Immunomodulation	Decreased activation of splenic effector CD4 + T cells and tumour‑infiltrating lymphocytes	PMID: 28270698
Segmented filamentous bacteria	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Immunomodulation	Gram‑positive commensals mediate accumulation of TH 17 and TH 1‑cell response	PMID: 28270698
Lactobacillus	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Immunomodulation	Gram‑positive commensals mediate accumulation of TH 17 and TH 1‑cell response	PMID: 28270698
Enterococcus hirae	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Translocation	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Lactobacillus murinus	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Translocation	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Lactobacillus johnsonii	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Translocation	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Enterococcus hirae	Doxorubicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Translocation	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Lactobacillus murinus	Doxorubicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Translocation	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Lactobacillus johnsonii	Doxorubicin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Translocation	Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs	PMID: 28270698
Mycoplasma	Gemcitabine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Enzymatic degradation	Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity	PMID: 28270698
Bacteroidetes	Ipilimumab	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	n.a.	Bacterially mediated B vitamin production and polyamine transport deficiencies associated with increased risk of CTLA‑4 blockade‑induced colitis	PMID: 28270698
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Efficacy; Increase Toxicity	n.a.	n.a.	Enzymatic degradation	Bacterial β‑glucuronidase cleaves glucuronide from inactive metabolite, releasing active metabolite (SN‑38) in the gut	PMID: 28270698
Bacteroides	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reduced diversity; ecological network function	Reduced diversity and shifts in relative abundance associated with chemotherapy‑induced diarrhoea	PMID: 28270698
Streptococcus	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reduced diversity; ecological network function	Reduced diversity and shifts in relative abundance associated with chemotherapy‑induced diarrhoea	PMID: 28270698
Unidentified gut microbes	Mesalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	N-acetylation by microbial N-acetyltransferases	Yield a inactive metabolite	PMID: 11344150; PMID: 28642381
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	sulfapyridine;5-ASA;N-acetyl 5-ASA	Decrease Efficacy	n.a.	n.a.	Reduce	Lack anti-inflammatory	PMID: 1425876; PMID: 28642381
Unidentified gut microbes	Ginsenosides	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Inhibit cytochrome P-450s;affect host xenobiotic metabolism	PMID: 16547074; PMID: 28642381
Unidentified gut microbes	Tryptophan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	antioxidant indole-3-propionic acid;the neurotransmitter tryptamine;indole	Increase Toxicity	n.a.	n.a.	n.a.	Generate the uremic toxin indoxyl sulfate	PMID: 17146590; PMID: 28642381
Unidentified gut microbes	Cysteine-S-conjugates of xenobiotics	Environmental Chemicals	Unclassified Substance	n.a.	thiol metabolites	n.a.	n.a.	n.a.	Cleave cysteine-S-conjugates of polychlorinated biphenyls by C-S β-lyases	Serve as a sole nitrogen,a potential role in nutrient acquisition	PMID: 20306345; PMID: 28642381
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Β-glucuronidase enzymes hydrolyze SN-38G;regenerate active agent	Cause intestinal damage and severe diarrhea;drug interaction:inhibitors	PMID: 21051639; PMID: 28642381
Unidentified gut microbes	Berberine	Herbal Substance	Medicinal Herbal Compounds	n.a.	n.a.	Increase Bioavailability	n.a.	n.a.	n.a.	Allow intestinal absorption	PMID: 26174047; PMID: 28642381
Unidentified gut microbes	Sulfoxide	Environmental Chemicals	Unclassified Substance	n.a.	n.a.	n.a.	n.a.	n.a.	Reduce the sulfoxide	n.a.	PMID: 3630204; PMID: 28642381
Unidentified gut microbes	Azo dyes	Environmental Chemicals	Industrial Chemicals and Pollutants	n.a.	mutagenic bis-aniline benzidine	Increase Toxicity	Conventional mice(not GF)	n.a.	n.a.	Increase carcinogen exposure	PMID: 3726894; PMID: 28642381
Unidentified gut microbes	Methylmercury	Environmental Chemicals	Industrial Chemicals and Pollutants; Toxic Agents	n.a.	inorganic mercury	Decrease Toxicity	Rat	n.a.	n.a.	Lead to less toxicity,facilitate mercury excretion	PMID: 626001; PMID: 28642381
Unidentified gut microbes	Amygdalin	Herbal Substance; Dietary Substance	Medicinal Herbal Compounds; Dietary Compounds	n.a.	mandelonitrile	Increase Toxicity	n.a.	n.a.	Hydrolyze the glycosidic linkage	Produce benzaldehydy and toxic cyanide	PMID: 7362642; PMID: 28642381
Unidentified gut microbes	Loperamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Reduce the N-oxide	n.a.	PMID: 7628301; PMID: 28642381
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	dihydrodigoxin	n.a.	Human; GF mice	n.a.	Flavin-dependent reductase(Cgr2)	n.a.	PMID: 28642381
Escherichia coli	Anticancer drugs	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Increase or decrease the efficacy of drug	PMID: 28642381
Listeria welshimeri	Anticancer drugs	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Increase or decrease the efficacy of drug	PMID: 28642381
Escherichia coli	CB954	Environmental Chemicals	Unclassified Substance	n.a.	n.a.	n.a.	n.a.	n.a.	Direct chemical modification	n.a.	PMID: 28642381
Escherichia coli	Fludarabine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Direct chemical modification	n.a.	PMID: 28642381
Escherichia coli	Gemcitabine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Direct chemical modification	n.a.	PMID: 28642381
Lactobacillus brevis	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	mtyramine	n.a.	n.a.	n.a.	Microbial decarboxylation and p-dehydroxylation(a tyrosine decarboxylase accepts L-dopa in vitro)	Contribute to the substantial variation	PMID: 28642381
Klebsiella	Phenoxyethanol	Therapeutic Substance	Approved Drug	n.a.	cyanuric acid	Increase Toxicity	Mouse	n.a.	Deaminate	Lead to renal toxicity	PMID: 28642381
Pseudomonas aeruginosa	Gluten	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	Elicit an enhanced gluten-specific immune response(compare with peptieds produced by Lactobacillus spp.from healthy individuals)	PMID: 28642381
Unidentified gut microbes	Thiazolidinediones	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Rat	Diet-induced obesity	n.a.	Indirectlyaffect gut bacteria(HFD leads to an increase in the relative abundance of Proteobacteria)	PMID: 27751827; PMID: 28973971
Unidentified gut microbes	Acarbose	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Human	Patients with hyperlipidemia or T2D	Prevent starch processing and absorption;	Enhance starch-fermenting and butyrate-producing bacteria;inhibit starch use by propionate-producing bacteria;increase Lactobacillus,Bifidobacterium and other SCFA-producing bacteria;associated with a diminution of Enterobacteriaceae,Bacteroidaceae and lecithinase positive Clostridum in human feces	PMID: 28973971
Escherichia coli	Acarbose	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Affect nutrient sources of bacteria	Block the growth of E.coli	PMID: 28973971
SCFA-producing bacteria	Antidiabetic drugs	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Positively influence the bacteria	PMID: 28973971
SCFA-producing bacteria	High-fiber diets	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Positively influence the bacteria	PMID: 28973971
Unidentified gut microbes	Incretin	Environmental Chemicals	Human Metabolite	n.a.	n.a.	n.a.	Primary murine colonic culture	n.a.	Microbiota fermentation products	Influence incretin secretion	PMID: 28973971
Unidentified gut microbes	Liraglutide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	High-fat diet(HFD),HF-fed,diabetes-induced	n.a.	Enrich Firmicutes;deplete Bacteroidetes,Proteobacteria and Actinobacteria phyla;enrich 13 phylotypes(Allobaculum,Turicibacter,Anaerostipes,Blautia,Lactobacillus,Butyricimonas,Desulfovibrio);decrease 20 phylotypes in the orders Clostridiales and Bacteroidales	PMID: 28973971
Escherichia	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Human	n.a.	Inhibit the dihydrofolate reductase activity of bacteria	Influence the side-effects of drug	PMID: 28973971
Bacteroides	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	SCFA-producing bacteria	Enric the bacteria	PMID: 28973971
Lactobacillus	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Positive effects	PMID: 28973971
Phascolarctobacterium	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	SCFA-producing bacteria	Enric the bacteria	PMID: 28973971
Blautia	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	SCFA-producing bacteria	Enric the bacteria	PMID: 28973971
Butyricicoccus	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	SCFA-producing bacteria	Enric the bacteria	PMID: 28973971
Bacteroidetes	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	High-fat diet(HFD)	n.a.	Decrease bacterial diversity	PMID: 28973971
Proteobacteria	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Positive effects	PMID: 28973971
Firmicutes	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	High-fat diet(HFD)	n.a.	Decrease bacterial diversity	PMID: 28973971
Verrucomicrobia	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Mouse	High-fat diet(HFD)	Genus Akkermansia	Increase the relative abundance of bacteria	PMID: 28973971
Bifidobacterium adolescentis	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Promote bacteria growth	Contribute to the glucose-lowering effect	PMID: 28973971
Allobaculum	Metformin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Positive effects	PMID: 28973971
Coriobacteriaceae	Miglitol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	A high fat and high glucose diet	Suppression of intestinal inflammation	Reverse the increase of bacteria	PMID: 28973971
Erysipelotrichaceae	Miglitol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	A high fat and high glucose diet	Suppression of intestinal inflammation	Reverse the increase of bacteria	PMID: 28973971
SCFA-producing bacteria	Physical activity	Environmental Chemicals	Unclassified Substance	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Positively influence the bacteria	PMID: 28973971
Proteobacteria	Pioglitazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	High-fat diet(HFD)	Correlate with the decrease of plasma endotoxin, TNF-α , IL-6 and MCP-1 levels	Reduce the abundance of bacteria	PMID: 28973971
Unidentified gut microbes	Saxagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	HF-fed,diabetic-induced	n.a.	Enrich Firmicutes,mainly the genera Lactobacillus,Allobaculum and Turicibacter;contain less Bacteroides and Prevotella;decrease the phylum Bacteroidetes	PMID: 28973971
Unidentified gut microbes	Sitagliptin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	Diabetes-induced	n.a.	Increase in the relative abundance of Bacteroidetes and Proteobacteria;decrease Firmicute;influence SCFA-producing bacteria;Lactobacillus and Bifidobacterium are depleted in feces	PMID: 28973971
Unidentified gut microbes	Voglibose	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Decrease the Firmicutes to Bacteroidetes ratio and higher the abundance in Verrucomicrobia	PMID: 28973971
Unidentified gut microbes	Mesalazine	Therapeutic Substance	Approved Drug	n.a.	acetylated 5-aminosalicylic acid	Increase Efficacy	n.a.	n.a.	N-acetyltransferases from bacteria	Exert physiopathological effects,increase activity	PMID: 11344150; PMID: 30227749
Unidentified gut microbes	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Lead to poor bioavailability of ranitidine	PMID: 11564550; PMID: 30227749
Unidentified gut microbes	Morphine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Hydrolysis of glucuronide	Increase drug toxicity	PMID: 1185599; PMID: 30227749
Unidentified gut microbes	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	N-oxide bond cleavage	Decrease activity	PMID: 30227749; PMID: 11955801
Unidentified gut microbes	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	M1 (demethylbutyryl metabolite), M4 (hydroxylated metabolite), M8 (the active hydroxy acid metabolite), and M9 (hydroxylated M8)	n.a.	Human; Rat	n.a.	n.a.	Produce four metabolites	PMID: 30227749; PMID: 24947972
Unidentified gut microbes	Deleobuvir	Therapeutic Substance	Investigational Drug	n.a.	CD 6168	n.a.	n.a.	n.a.	An alkene reduction by the gut microbiota	n.a.	PMID: 30227749; PMID: 26068924
Unidentified gut microbes	Amlodipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Efficacy	n.a.	n.a.	n.a.	Increase activity	PMID: 30227749; PMID: 26630218
Unidentified gut microbes	Epacadostat	Therapeutic Substance	Investigational Drug	n.a.	Amidine metabolite	Decrease Efficacy	n.a.	n.a.	n.a.	Decrease activity	PMID: 30227749; PMID: 27457784
Unidentified gut microbes	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Amine formation	n.a.	PMID: 30227749; PMID: 4165044
Unidentified gut microbes	Sulfanilamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Azoreductase enzymes,Activation of azo-bond containing prodrug to sulfanilamid	Increase toxicity	PMID: 5173017; PMID: 30227749
Unidentified gut microbes	Sulfonamide antibiotics	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Microbial transformation	n.a.	PMID: 5173017; PMID: 30227749
Unidentified gut microbes	Clonazepam	Therapeutic Substance	Approved Drug	n.a.	7-aminoclonazepam	Increase Toxicity	n.a.	n.a.	Nitro reduction	n.a.	PMID: 6506755; PMID: 30227749
Unidentified gut microbes	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Isoxazole scission or hydroxylation	Decrease activity	PMID: 7512019; PMID: 30227749
Unidentified gut microbes	Loperamide oxide	Therapeutic Substance	Investigational Drug	n.a.	active drug loperamide	Increase Efficacy	Human; Dog; Rat	n.a.	n.a.	Make the metabolism and increase activity of loperamide oxide	PMID: 7628301; PMID: 30227749
Unidentified gut microbes	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	No alteration of pharmacokinetics	PMID: 7629748; PMID: 30227749
Unidentified gut microbes	Calcitonin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Susceptible to proteolysis,Protease	Increase large-intestinal absorption,decrease activity	PMID: 30227749; PMID: 9055189
Unidentified gut microbes	Insulin human	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Susceptible to proteolysis,Protease	Increase large-intestinal absorption,decrease activity	PMID: 30227749; PMID: 9055189
Unidentified gut microbes	Cimetidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Influence drug delivery and absorption	PMID: 30227749
Unidentified gut microbes	Famotidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Influence drug delivery and absorption	PMID: 30227749
Unidentified gut microbes	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Influence drug delivery and absorption	PMID: 30227749
Bacteroides	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	(E)-5-(2-bromovinyl)uracil	Decrease Efficacy	n.a.	n.a.	n.a.	Reduce activity	PMID: 30227749
Clostridioides difficile	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Decrease Efficacy; Increase Toxicity	n.a.	n.a.	P-cresol(microbial metabolite) reduces metabolic clearance	Reduce activity;delay the metabolism of drug in the human body and increase risk of hepatotoxicity	PMID: 30227749
Enterobacteriales	Acetylsalicylic acid	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Efficacy	n.a.	n.a.	n.a.	Modulate the metabolism and pharmacokinetics;Potentiate the therapeutic potency	PMID: 30227749
Enterococcus	Acetylsalicylic acid	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Efficacy	n.a.	n.a.	n.a.	Modulate the metabolism and pharmacokinetics;Potentiate the therapeutic potency	PMID: 30227749
Lactobacillus	Acetylsalicylic acid	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Efficacy	n.a.	n.a.	n.a.	Modulate the metabolism and pharmacokinetics;Potentiate the therapeutic potency	PMID: 30227749
Escherichia coli Nissle 1917	Amiodarone	Therapeutic Substance	Approved Drug	n.a.	DEA	Increase Efficacy; Increase Bioavailability	Animal model	n.a.	n.a.	Increase bioavailability of AMI,increase plasma levels of desethylamiodarone(DEA),promote the absorption of AMI and increase the activity of CYP2C	PMID: 30227749
Clostridium sp.	Balsalazide	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid	Increase Toxicity	n.a.	n.a.	Reduction and Release of 5-aminosalicylic acid;Azoreductases	Increase toxicity	PMID: 30227749
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	digoxigenin,or dihydrodigoxin	Decrease Efficacy	human	n.a.	Reduction	Produce inactive metabolites;[interaction]:(gnotobiotic mice)dietary protein reduces microbial metabolism of digoxin(vivo) and changes drug concentration(in the serum and urine);[drug interaction]:antibiotics(tetracycline or erythromycin) increase plasma concentration of digoxin	PMID: 30227749
Bacteroides	Glucuronides	Environmental Chemicals	Unclassified Substance	n.a.	diclofenac,ketoprofen,indomethacin	Increase Toxicity	n.a.	n.a.	Hydrolysis of the glycosidicbon	Increase toxicity	PMID: 30227749
Clostridium	Glucuronides	Environmental Chemicals	Unclassified Substance	n.a.	diclofenac,ketoprofen,indomethacin	Increase Toxicity	n.a.	n.a.	Hydrolysis of the glycosidicbon	Increase toxicity	PMID: 30227749
Bifidobacterium sp.	Glucuronides	Environmental Chemicals	Unclassified Substance	n.a.	diclofenac,ketoprofen,indomethacin	Increase Toxicity	n.a.	n.a.	Hydrolysis of the glycosidicbon	Increase toxicity	PMID: 30227749
Escherichia coli	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	Increase Toxicity	n.a.	n.a.	Hydrolysis of the glycosidicbon,bacterial b-glucuronidases	Increase toxicity	PMID: 30227749
Bacteroides vulgatus	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	Increase Toxicity	n.a.	n.a.	Hydrolysis of the glycosidicbon,bacterial b-glucuronidases	Increase toxicity	PMID: 30227749
Erysipelatoclostridium ramosum	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	Increase Toxicity	n.a.	n.a.	Hydrolysis of the glycosidicbon,bacterial b-glucuronidases	Increase toxicity	PMID: 30227749
Bacteroides	Lactulose	Therapeutic Substance	Approved Drug	n.a.	lactic and acetic acidsactive metabolite	Decrease Efficacy	n.a.	n.a.	n.a.	Reduce activity	PMID: 30227749
Clostridium	Lactulose	Therapeutic Substance	Approved Drug	n.a.	lactic and acetic acidsactive metabolite	Decrease Efficacy	n.a.	n.a.	n.a.	Reduce activity	PMID: 30227749
Lactobacillus	Lactulose	Therapeutic Substance	Approved Drug	n.a.	lactic and acetic acidsactive metabolite	Decrease Efficacy	n.a.	n.a.	n.a.	Reduce activity	PMID: 30227749
Bacteroides	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Efficacy	n.a.	n.a.	Thiazole ring opening	Increase activity	PMID: 30227749
Clostridium sp.	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Efficacy	n.a.	n.a.	Thiazole ring opening	Increase activity	PMID: 30227749
Unidentified gut microbes	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Catalyze p-dehydroxylation of L-dopa to mhydroxyphenylacetic acid	n.a.	PMID: 30227749
Helicobacter pylori	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Decrease Bioavailability	Human	Patients with Parkinson’s disease (PD)	Dehydroxylation	Reduce acute L-dopa absorption;reduce L-dopa onset time, ON duration, motor severity, and quality of life parameters	PMID: 30227749
Clostridium perfringens	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	N-(2-hydroxyethyl)-oxamic acid and acetamide	Decrease Efficacy	n.a.	n.a.	Reduction	Reduce activity	PMID: 30227749
[Clostridium] leptum	Nitrazepam	Therapeutic Substance	Approved Drug	n.a.	7-acetylaminonitrazepam	Decrease Toxicity	n.a.	n.a.	Nitroreductase	Produce teratogenic activity metabolites,Induce teratogenicity	PMID: 30227749
Clostridium sp.	Olsalazine	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid	Increase Toxicity	n.a.	n.a.	Reduction and Release of 5-aminosalicylic acid;Azoreductases	Increase toxicity	PMID: 30227749
Lactobacillus	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Affect the pharmacokinetics and pharmacodynamics;increase the risk of myopathy	PMID: 30227749
Clostridium sp.	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid	Increase Toxicity	n.a.	n.a.	Reduction and Release of 5-aminosalicylic acid;Azoreductases	Increase toxicity	PMID: 30227749
Clostridium sporogenes	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	2-sulphamoylacetylphenol	Increase Efficacy	n.a.	n.a.	Zonisamide reductase	Increase activity	PMID: 30227749
Pseudomonas fluorescens	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reductive metabolism	n.a.	PMID: 30227749
Escherichia coli	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reductive metabolism	n.a.	PMID: 30227749
Bacteroides vulgatus	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reductive metabolism	n.a.	PMID: 30227749
Enterococcus faecalis	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reductive metabolism	n.a.	PMID: 30227749
Clostridium sporogenes	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reductive metabolism	n.a.	PMID: 30227749
Bifidobacterium bifidum	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reductive metabolism	n.a.	PMID: 30227749
Lactobacillus rhamnosus	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reductive metabolism	n.a.	PMID: 30227749
Salmonella enterica subsp. enterica serovar Typhimurium	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reductive metabolism	n.a.	PMID: 30227749
Eubacterium sp.	Balsalazide	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid	Increase Toxicity	n.a.	n.a.	Reduction and Release of 5-aminosalicylic acid;Azoreductases	Increase toxicity	PMID: 30227749
Unidentified gut microbes	Diclofenac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Bacterial b-glucuronidases	Reduce intestinal tract toxicity	PMID: 30227749
Unidentified gut microbes	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Bacterial b-glucuronidases	Reduce intestinal tract toxicity	PMID: 30227749
Unidentified gut microbes	Ketoprofen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Bacterial b-glucuronidases	Reduce intestinal tract toxicity	PMID: 30227749
Eubacterium sp.	Olsalazine	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid	Increase Toxicity	n.a.	n.a.	Reduction and Release of 5-aminosalicylic acid;Azoreductases	Increase toxicity	PMID: 30227749
Eubacterium sp.	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	5-aminosalicylic acid	Increase Toxicity	n.a.	n.a.	Reduction and Release of 5-aminosalicylic acid;Azoreductases	Increase toxicity	PMID: 30227749
Unidentified gut microbes	Mesalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	N-acetyltransferase	Acetylating to acid	PMID: 11344150; PMID: 30338735
Unidentified gut microbes	Nizatidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Metabolized by bacteria	n.a.	PMID: 30338735; PMID: 11955801
Unidentified gut microbes	Sulfonamide antibiotics	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Azoreductase enzymes	Activation of prodrug to 5-aminosalicylic acid	PMID: 30338735; PMID: 1711964
Clostridium perfringens	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reduction to acetamide	PMID: 30338735; PMID: 231450
Bacterium DZY-HS11	Arsenic	Environmental Chemicals	Toxic Agents	n.a.	n.a.	n.a.	Mouse	n.a.	Reduce the abundance of bacteria	n.a.	PMID: 30338735; PMID: 24413286
Unidentified gut microbes	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Β-D-glucosidase, α-L-rhamnosidase,α-D-glucosidase enzyme	Drug interaction:antibiotics can reduce the biotransformation	PMID: 30338735; PMID: 24947972
Unidentified gut microbes	Digitoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Β-glucuronidase	Hydrolysis of glucuronide	PMID: 28922; PMID: 30338735
Unidentified gut microbes	Nifedipine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	n.a.	PMID: 30338735; PMID: 29790376
Unidentified gut microbes	Nifedipine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	Hypoxic conditions at high altitudes	Changes of intestinal microflora caused by high plateau hypoxia	Increase the bioavailability of drug	PMID: 30338735; PMID: 29790376
Unidentified gut microbes	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	n.a.	Result in increased toxicity	PMID: 30338735; PMID: 430360
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	sulfapyridine and 5-ASA	Decrease Efficacy	n.a.	n.a.	n.a.	Lose activity	PMID: 30338735; PMID: 4402374
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Active 5-aminosalicyclic acid by intestinal azoreductase enzymes	Increase the drug	PMID: 30338735; PMID: 4402374
Unidentified gut microbes	Dihydroxyphenylalanine (DOPA)	Therapeutic Substance	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Direct dopa to alternative metabolic pathways	PMID: 4723308; PMID: 30338735
Unidentified gut microbes	Artificial sweetener cyclamate	Dietary Substance	Dietary Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Hydrolysis	n.a.	PMID: 7362642; PMID: 30338735
Unidentified gut microbes	Plant-derived glycosides(amygdalin)	Herbal Substance	Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Hydrolysis	n.a.	PMID: 7362642; PMID: 30338735
Unidentified gut microbes	Loperamide oxide	Therapeutic Substance	Investigational Drug	n.a.	loperamide	n.a.	Human; Dog; Rat	n.a.	Bacteria affect activation of prodrugs and drug inactivation	n.a.	PMID: 30338735; PMID: 7628301
Unidentified gut microbes	Nitrazepam	Therapeutic Substance	Approved Drug	n.a.	7-acetylaminonitrazepam	n.a.	n.a.	n.a.	Nitroreductase	n.a.	PMID: 30338735; PMID: 9310649
Clostridium	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	p-cresol	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 30338735
Enterobacteriales	Acetylsalicylic acid	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug interaction:antibiotics can potentiate the therapeutic potency	PMID: 30338735
Enterococcus	Acetylsalicylic acid	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug interaction:antibiotics can potentiate the therapeutic potency	PMID: 30338735
Lactobacillus	Acetylsalicylic acid	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug interaction:antibiotics can potentiate the therapeutic potency	PMID: 30338735
Unidentified gut microbes	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	calycosin	n.a.	n.a.	n.a.	Bacteria produces O-methyltransferase and aromatic hydroxylase	n.a.	PMID: 30338735
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	dihydrodigoxigenin,dihydrodigoxin	Decrease Efficacy	n.a.	n.a.	Reduction to inactive metabolites	n.a.	PMID: 30338735
Escherichia	Diosmin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by diosmetin	n.a.	PMID: 30338735
Enterococcus	Diosmin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by diosmetin	n.a.	PMID: 30338735
Clostridium	Diosmin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by diosmetin	n.a.	PMID: 30338735
Lactobacillus	Diosmin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by diosmetin	n.a.	PMID: 30338735
Bifidobacterium	Diosmin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by diosmetin	n.a.	PMID: 30338735
Bacteroides	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	n.a.	n.a.	n.a.	Hydrolysis and release of SN-38	Leads to GI toxicity	PMID: 30338735
Clostridium	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	n.a.	n.a.	n.a.	Hydrolysis and release of SN-38	Leads to GI toxicity	PMID: 30338735
Escherichia coli	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Β-glucuronidases	Enhance the irinotecan toxicity	PMID: 30338735
Bacteroides vulgatus	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Β-glucuronidases	Enhance the irinotecan toxicity	PMID: 30338735
Erysipelatoclostridium ramosum	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Β-glucuronidases	Enhance the irinotecan toxicity	PMID: 30338735
Bifidobacterium sp.	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	n.a.	n.a.	n.a.	Hydrolysis and release of SN-38	Leads to GI toxicity	PMID: 30338735
Bacteroides	Lactulose	Therapeutic Substance	Approved Drug	n.a.	acetic lactic,acids active	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 30338735
Clostridium	Lactulose	Therapeutic Substance	Approved Drug	n.a.	acetic lactic,acids active	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 30338735
Lactobacillus	Lactulose	Therapeutic Substance	Approved Drug	n.a.	acetic lactic,acids active	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 30338735
Bacteroides	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	levametabol-I,levametabol-III	Increase Efficacy	n.a.	n.a.	n.a.	Generate active metabolites	PMID: 30338735
Clostridium sp.	Levamisole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	levametabol-I,levametabol-III	Increase Efficacy	n.a.	n.a.	n.a.	Generate active metabolites	PMID: 30338735
[Eubacterium] rectale	Puerarin	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	daidzein	n.a.	n.a.	n.a.	Convert by bacteria	n.a.	PMID: 30338735
Bacteroides	Rutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by quercetin	n.a.	PMID: 30338735
Clostridium	Rutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by quercetin	n.a.	PMID: 30338735
Lactobacillus	Rutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by quercetin	n.a.	PMID: 30338735
Eubacterium	Rutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by quercetin	n.a.	PMID: 30338735
Bifidobacterium sp.	Rutin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond, followed by quercetin	n.a.	PMID: 30338735
Escherichia	Scutellaria baicalensis root	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond,followed by baicalein.	n.a.	PMID: 30338735
Streptococcus	Scutellaria baicalensis root	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond,followed by baicalein.	n.a.	PMID: 30338735
Lactobacillus	Scutellaria baicalensis root	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond,followed by baicalein.	n.a.	PMID: 30338735
Eubacterium	Scutellaria baicalensis root	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond,followed by baicalein.	n.a.	PMID: 30338735
Bifidobacterium sp.	Scutellaria baicalensis root	Therapeutic Substance	Investigational Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Generated to glycosidic bond,followed by baicalein.	n.a.	PMID: 30338735
Lactobacillus	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	n.a.	Increase the risk of myopathy	PMID: 30338735
Bacteroides	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	(E)-5-(2-bromovinyl) uracil	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 30338735
Gardnerella	Tenofovir	Therapeutic Substance	Investigational Drug	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Catabolized tenofovir into an inactive compound	n.a.	PMID: 30338735
Clostridium	Zonisamide	Therapeutic Substance	Approved Drug	n.a.	2-sulphamoylacetylphenol	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 30338735
Unidentified gut microbes	Daidzein	Therapeutic Substance; Herbal Substance	Investigational Drug; Medicinal Herbal Compounds	n.a.	Calycosin	n.a.	n.a.	n.a.	Aromatic hydroxylase,O-methyltransferase	n.a.	PMID: 30338735
Faecalibacterium prausnitzii	Anti‑PD‑1 therapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Human	Patients with metastatic melanoma	n.a.	Higher relative abundance of bacteria in responding (R) patients;therapy is defined by eight species driven by Bifidobacterium longum	PMID: 30530851
Bifidobacterium longum	Anti‑PD‑1 therapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Human	Patients with metastatic melanoma	n.a.	Higher relative abundance of bacteria in responding (R) patients;therapy is defined by eight species driven by Bifidobacterium longum	PMID: 30530851
Akkermansia muciniphila	Anti‑PD‑1 therapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Human	Patients with non-small cell lung cancer	n.a.	Increased relative abundance of bacteria in PD-1 R	PMID: 30530851
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Efficacy	Human	n.a.	n.a.	221% increase in simvastatin AUC for homozygotes	PMID: 19833260; PMID: 18650507; PMID: 24918167; PMID: 22380001; PMID: 31171383
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Lactone ring reduction	n.a.	Increase Toxicity	Human	n.a.	n.a.	Decreased AUC; narrow therapeutic window	PMID: 24637603; PMID: 18334914; PMID: 31171383
Unidentified gut microbes	Warfarin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Human	n.a.	Vitamin K production	Altered activity of drug	PMID: 22380001; PMID: 17042764; PMID: 26962786; PMID: 31171383
Unidentified gut microbes	Bromazepam	Therapeutic Substance	Approved Drug	Nitroreduction	n.a.	Increase Toxicity	Human	n.a.	n.a.	Amino-metabolite generation, Inactivation	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Bromazepam	Therapeutic Substance	Approved Drug	Nitroreduction	n.a.	Decrease Efficacy	Human	n.a.	n.a.	Change to inactive metabolite	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Clonazepam	Therapeutic Substance	Approved Drug	Nitroreduction	n.a.	Increase Toxicity	Human	n.a.	n.a.	Amino-metabolite generation, Inactivation	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Clonazepam	Therapeutic Substance	Approved Drug	Nitroreduction	n.a.	Decrease Efficacy	Human	n.a.	n.a.	Change to inactive metabolite	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Diclofenac	Therapeutic Substance	Approved Drug	Deglucuronidation	n.a.	Increase Toxicity	Human	n.a.	n.a.	Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Indomethacin	Therapeutic Substance	Approved Drug	Deglucuronidation	n.a.	Increase Toxicity	Human	n.a.	n.a.	Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	Deglucuronidation	n.a.	Increase Toxicity	Human	n.a.	n.a.	Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Ketoprofen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Deglucuronidation	n.a.	Increase Toxicity	Human	n.a.	n.a.	Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Nitrazepam	Therapeutic Substance	Approved Drug	Nitroreduction	n.a.	Increase Toxicity	Human	n.a.	n.a.	Amino-metabolite generation, Inactivation	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Nitrazepam	Therapeutic Substance	Approved Drug	Nitroreduction	n.a.	Decrease Efficacy	Human	n.a.	n.a.	Change to inactive metabolite	PMID: 27591027; PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	Deglucuronidation	SN-38G metabolite	Increase Toxicity	Human	n.a.	n.a.	Defect in glucuronidation; increased toxicity	PMID: 29104759; PMID: 18349289; PMID: 31171383
Unidentified gut microbes	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Sulfonation	n.a.	Decrease Toxicity	Human	n.a.	n.a.	Increased rate of glucuronidation; decreased risk of liver failure	PMID: 23408116; PMID: 19667173; PMID: 29705271; PMID: 31171383
Unidentified gut microbes	Brivudine	Therapeutic Substance	Approved Drug	n.a.	additional bromovinyluracil	Increase Toxicity	Human	n.a.	n.a.	Hepatotoxicity; bromovinyluracil prevents clearance of 5-FU	PMID: 9690942; PMID: 30733391; PMID: 31171383
Unidentified gut microbes	Sorivudine	Therapeutic Substance	Investigational Drug	n.a.	additional bromovinyluracil	Increase Toxicity	Human	n.a.	n.a.	Hepatotoxicity; bromovinyluracil prevents clearance of 5-FU	PMID: 9690942; PMID: 30733391; PMID: 31171383
Unidentified gut microbes	Balsalazide	Therapeutic Substance	Approved Drug	Azoreduction	local 5-ASA	Increase Efficacy	Human	n.a.	n.a.	Prodrug activation: local 5-ASA release	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Calcitonin	Therapeutic Substance	Approved Drug	Proteolysis	n.a.	Decrease Efficacy	Human	n.a.	n.a.	Breakdown of therapeutic protein	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Chloramphenicol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Nitroreduction	p-aminophenyl-2-amino-1,3-propanediol	Increase Toxicity	Human	n.a.	n.a.	Bone marrow toxicity	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Insulin human	Therapeutic Substance	Approved Drug	Proteolysis	n.a.	Decrease Efficacy	Human	n.a.	n.a.	Breakdown of therapeutic protein	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Ipsalazide	Therapeutic Substance	Approved Drug	Azoreduction	local 5-ASA	Increase Efficacy	Human	n.a.	n.a.	Prodrug activation: local 5-ASA release	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Neoprontosil	Therapeutic Substance	Approved Drug	Azoreduction	n.a.	Increase Efficacy	Human	n.a.	n.a.	Antibiotic activation	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Olsalazine	Therapeutic Substance	Approved Drug	Azoreduction	local 5-ASA	Increase Efficacy	Human	n.a.	n.a.	Prodrug activation: local 5-ASA release	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Picosulfuric acid	Therapeutic Substance	Approved Drug	Desulfation	n.a.	Increase Efficacy	Human	n.a.	n.a.	Solubility increase	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Prontosil	Therapeutic Substance	Approved Drug	Azoreduction	n.a.	Increase Efficacy	Human	n.a.	n.a.	Antibiotic activation	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Sulfadiazine	Therapeutic Substance	Approved Drug	Azoreduction	local 5-ASA	Increase Efficacy	Human	n.a.	n.a.	Prodrug activation: local 5-ASA release	PMID: 27591027; PMID: 31171383
Unidentified gut microbes	Mesalazine	Therapeutic Substance	Approved Drug	N-Acetylation	n.a.	Decrease Efficacy	Human	n.a.	n.a.	Less efficacy; possible pancreatic toxicity	PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Amiodarone	Therapeutic Substance	Approved Drug	N-dealkylation	n.a.	Increase Efficacy	Human	n.a.	n.a.	Increased bioavailability of active metabolite	PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Codeine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Deglucuronidation	n.a.	Increase Efficacy	Human	n.a.	n.a.	Reformation of active metabolite	PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Lactone ring reduction	n.a.	Decrease Efficacy	Human	n.a.	n.a.	Change to inactive metabolite	PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Metamfetamine	Therapeutic Substance	Approved Drug	N-Demethylation	n.a.	Decrease Efficacy	Human	n.a.	n.a.	Change to inactive metabolite	PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Morphine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Deglucuronidation	n.a.	Increase Efficacy	Human	n.a.	n.a.	Reformation of active metabolite	PMID: 30227749; PMID: 31171383
Unidentified gut microbes	Brivudine	Therapeutic Substance	Approved Drug	N-Dealkylation	n.a.	Increase Toxicity	Human	n.a.	n.a.	Bacteroides-mediated hepatotoxicity; potentially fatal 5-FU accumulation	PMID: 30733391; PMID: 31171383
Unidentified gut microbes	Sorivudine	Therapeutic Substance	Investigational Drug	N-Dealkylation	n.a.	Increase Toxicity	Human	n.a.	n.a.	Bacteroides-mediated hepatotoxicity; potentially fatal 5-FU accumulation	PMID: 30733391; PMID: 31171383
Helicobacter pylori	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	P-Dehydroxylation	n.a.	Decrease Efficacy	Human	n.a.	n.a.	Decrease in L-dopa absorption	PMID: 31171383
Pseudomonas aeruginosa	Morphine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	Deglucuronidation	morphine-glucuronide metabolite	n.a.	Human	n.a.	n.a.	Decreased clearance of morphine; Induces virulence in some strains of Pseudomonas aeruginosa	PMID: 31171383
Unidentified gut microbes	Estradiol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Increase Bioavailability	human	n.a.	Β-glucuronidase mediate deconjugation and enterohepatic circulation of estrogen	Greater absroption of estrogens;develop estrogen-driven cancer	PMID: 27107051; PMID: 31184303; PMID: 24187630
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	Human; Mouse	n.a.	Microbial β-glucuronidases mediate the reactivation of metabolite（deconjugation and reactivation of SN-38）	Cause toxicity(epithelial damage;severe diarrhea);analog:plant-based compound scutellarin(inadvertently modulating the effect of cancer therapy)	PMID: 29104759; PMID: 21051639; PMID: 31184303
Unidentified gut microbes	Taurine conjugated bile acid	Environmental Chemicals	Human Metabolite	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Meidate de-conjugation of taurineconjugates;generate hydrogen sulfid	Contribute to the etiology of cancer	PMID: 27003186; PMID: 31184303
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Decrease Efficacy	human	n.a.	Be linked to cgr operon expression levels;human microbiome reductase inactivates the drug	Lead to inactivation and decreased bioavailability;drug substructure similarity:cardenolides(great),progesterone、cortisone(bad);	PMID: 31184303
Unidentified gut microbes	Altretamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	Human	n.a.	Alter the drug structure	Cause diarrhea and kidney damage;interaction:tamoxifen、diphenhydramine、theobromine	PMID: 31184303
Pseudomonas putida	Altretamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Microbial N-demethylase enzymes	Lead to similar toxic effects as seen with melamine;Substrate similar(no evidence)	PMID: 31184303
Styrax aureus	Hypochlorite	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Human	Patients with cutaneous T cell lymphoma	n.a.	Reduce the amount of bacteria	PMID: 18835065; PMID: 31186074
Unidentified probiotic	Common azole treatment	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Reduce the amount of azoleresistant fungal strains	PMID: 25362524; PMID: 31186074
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Reactivate drug by the β-glucuronidase enzyme	Result in side effects( stage 4 diarrhea and gastrointestinal damage)	PMID: 31186074; PMID: 26364932
Unidentified gut microbes	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	m-tyramine, m-hydroxyphenylacetic acid (m-HPAA)	Decrease Efficacy	Rat	n.a.	n.a.	Decrease L-DOPA half-life and efficacy	PMID: 4723308; PMID: 31186074
Unidentified gut microbes	Lactulose	Therapeutic Substance	Approved Drug	n.a.	acetic,lactic acid	Increase Efficacy	n.a.	n.a.	n.a.	Product therapeutic metabolites	PMID: 6804597; PMID: 31186074
Unidentified gut microbes	Antibiotic (extensive treatment)	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Eliminate the majority of the intestinal microbiome and improve harmful bacteria(Clostridium difficile)	Lead to intestinal complications(antibiotic-associated diarrhea and colitis);drug interaction: C. difficile can be treated with vancomycin and metronidazole	PMID: 31186074
Unidentified gut microbes	Bromazepam	Therapeutic Substance	Approved Drug	n.a.	7-aminoclonazepam,2-(2-amino-5-bromobenzoyl) pyridine	n.a.	n.a.	n.a.	Gut microbial nitroreductase activity	n.a.	PMID: 2893665; PMID: 6506755
Unidentified gut microbes	Clonazepam	Therapeutic Substance	Approved Drug	n.a.	7-aminoclonazepam,2-(2-amino-5-bromobenzoyl) pyridine	n.a.	n.a.	n.a.	Gut microbial nitroreductase activity	n.a.	PMID: 2893665; PMID: 6506755
Unidentified gut microbes	Potassium oxonate	Environmental Chemicals	Unclassified Substance	n.a.	cyanuric acid	n.a.	n.a.	n.a.	n.a.	n.a.	PMID: 10997934
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	N-acetyl sulfapyridine,N-acetyl-5-aminosalicylic acid	n.a.	Human; Rat; Guinea pig; Dog	n.a.	Bacterial N-acetylation	n.a.	PMID: 1425876
Unidentified gut microbes	Picosulfuric acid	Therapeutic Substance	Approved Drug	n.a.	4,40-dihydroxydiphenyl-(2 pyridyl)-methane	n.a.	n.a.	n.a.	Conversion by gut bacteria	n.a.	PMID: 1507649
Unidentified gut microbes	Phosphate or sulfate ester prodrugs	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	The drug act on hydrolytic enzymes of bacteria	n.a.	PMID: 1507649
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	5-amino 5-salicylic acid	Increase Efficacy	n.a.	n.a.	Microbial azoreductases	Convert to its pharmacologically active form;enhance drug distribution：olsalazine、balsalazide（inflammatory bowel disease）——introduction of azo bonds	PMID: 18305431
Unidentified gut microbes	Antibiotic	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Eliminate vitamin K-producing bacteria	Lead to alteration in coagulation status	PMID: 18841274
Unidentified gut microbes	Nitrazepam	Therapeutic Substance	Approved Drug	n.a.	7-aminonitrazepam,7-acetylaminonitrazepam	Increase Toxicity	Rat	Pregnant	Gut microbial nitroreductase activity	Lead to nitrazepam-related teratogenicity;drug interaction:antibiotic reduced metabolites	PMID: 1925980
Unidentified gut microbes	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	N-acetyl p-benzoquuinone imine	Increase Toxicity	Human	n.a.	A microbial-derived metabolite p-cresol compete with acetaminophen	Impede the ability for the liver to detoxify	PMID: 19667173; PMID: 31462078
Unidentified anaerobic bacterium	Fostamatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	Microbial O-dealkylation	n.a.	PMID: 20371637
Unidentified gut microbes	Rosuvastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Toxicity	n.a.	n.a.	Compete with TMA for metabolism by FMO3	Cause side effect on fish odor syndrom	PMID: 21422137
Unidentified gut microbes	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	n.a.	n.a.	Alterations in bacteria(expansion of proinflammatory bacteria)	PMID: 22328575
Unidentified gut microbes	Metronidazole	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	1-(2-aminoimidazol-1-yl)-3 methoxypropanol-2-ol and acetamide	n.a.	Rat	n.a.	Gut microbiome–derived nitroreduction	Lead to rat carcinogen	PMID: 231450
Unidentified gut microbes	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	n.a.	Microbial inactivation	PMID: 23869020
Unidentified gut microbes	CpG-oligonucleotide immunotherapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Prime murine immune cells to secrete tumor necrosis factor(TNF)	Stimulate the immune system to attack cancer cells	PMID: 24264989
Unidentified gut microbes	Lovastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Drug interaction:long-term antibiotic treatment might lead to a failure to control serum cholesterol levels	PMID: 24947972
Unidentified gut microbes	Sulfasalazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Efficacy	n.a.	n.a.	n.a.	Lead to activation of drug	PMID: 25091594
Unidentified gut microbes	Eltrombopag	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Human; Dog	n.a.	Reductive cleavag	n.a.	PMID: 25581726
Unidentified gut microbes	Levosimendan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Human; Dog	n.a.	Reductive cleavag	n.a.	PMID: 25581726
Unidentified gut microbes	Indole	Therapeutic Substance; Herbal Substance	Investigational Drug	n.a.	indole-3-propionic acid	n.a.	n.a.	n.a.	n.a.	Provide ligands for the aryl hydrocarbon receptor	PMID: 26041783
Unidentified gut microbes	Tryptophan	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	indole-3-propionic acid	n.a.	n.a.	n.a.	n.a.	Provide ligands for the aryl hydrocarbon receptor	PMID: 26041783
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	B-glucuronidase activity	Lead to severe diarrhea;drug interaction:antibiotic mixtures(streptomycin,penicillin or neomycin and bacitracin)eliminated fecal b-glucuronidase activity; TJ-14 administration moderate weight loss and delay the drug-associated diarrhea; the P-glycoprotein and (cMOA T/MRP2) inhibitor of cyclosporin A or (UDP)-glucuronosyltransferase inhibitor valproic acid increased intestinal toxicity	PMID: 26518357
Unidentified gut microbes	Indomethacin	Therapeutic Substance	Approved Drug	n.a.	n.a.	Increase Efficacy	Mouse	n.a.	Β-glucuronidases	Enhance pharmacological effect	PMID: 26701907
Unidentified oral microbes	PPIs	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Associated with changes toward a less healthy gut microbiome and in line with changes predisposing users to infection with C. difficile	Species of bacteria were seen to be over-represented in the fecal microbiome	PMID: 26719299
Unidentified gut microbes	PPIs	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	n.a.	n.a.	Changes in bacterial populations(decrease Bacteroidetes and increase Firmicutes)	Predispose PPI-treated subjects to C. difficile infection;[drug interaction]:frequent use of PPIs can exacerbate NSAID-induced small intestinal injury;[probiotics]prevent NSAID-induced damage in patients receiving PPI and NSAIDs	PMID: 26923470
Unidentified gut microbes	Rosuvastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	With rosuvastatin	Reduce hepatic expression of the CYP27a1,alter the concentrations of bile acids	Contribute to the composition of gut microbiota	PMID: 28209601
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	n.a.	Decrease Toxicity	n.a.	n.a.	n.a.	Causes toxic side effects	PMID: 29104759
Unidentified gut microbes	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	dopamine	n.a.	n.a.	n.a.	Tyrosine decarboxylase	n.a.	PMID: 30659181
Escherichia coli	Flucytosine	Therapeutic Substance	Approved Drug	n.a.	5-FU	n.a.	n.a.	n.a.	Deamination by bacteria	n.a.	PMID: 3729334
Unidentified gut microbes	2-amino-3,6-dihydro-3H-imidazo[4,5-f]quinoline	Environmental Chemicals	Unclassified Substance	n.a.	7-hydroxy metabolite	n.a.	n.a.	n.a.	Gut microbiotal oxidation/dehydrogenation	n.a.	PMID: 3821779
Unidentified gut microbes	Acetaminophen	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	n.a.	n.a.	Drug is deacetylated	n.a.	PMID: 4418213
Unidentified gut microbes	Phenacetin	Therapeutic Substance	Approved Drug (Withdrawn)	n.a.	n.a.	n.a.	n.a.	n.a.	Drug is deacetylated	n.a.	PMID: 4418213
Unidentified gut microbes	Levodopa	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	m-hydroxyphenylacetic acid	n.a.	Rat	n.a.	Some microbial dehydroxylation	Reduce the exposure of the drug in the brain	PMID: 5343357
Unidentified gut microbes	Methotrexate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	Normal	n.a.	n.a.	PMID: 5345205
Unidentified gut microbes	Radiation sensitizer misonidazole	Therapeutic Substance	n.a.	n.a.	l-(2-l-(2-aminoimidazol-l-yl)-3-methoxypropan-2-ol	n.a.	Rat	Normal,germ-free(GF)	Nitroreduction	Drug interaction:penicillin increased drug exposure and decreased neurotoxicity	PMID: 6260109
Unidentified gut microbes	Risperidone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat; Dog	n.a.	Reductive metabolism	n.a.	PMID: 7512019
Unidentified gut microbes	Calcitonin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Drug is rapidly degraded;more prone to proteolysis;drug interaction:protease inhibitors(camostat/aprotinin) improve the stability and bioavailability of these peptides	PMID: 7550138
Unidentified gut microbes	Loperamide oxide	Therapeutic Substance	Investigational Drug	n.a.	loperamide,the ranitidine,nitazidine	n.a.	Dog	n.a.	n.a.	n.a.	PMID: 7628301
Unidentified gut microbes	Omeprazole	Therapeutic Substance	Approved Drug	n.a.	sulfide metabolite	n.a.	n.a.	n.a.	Reduction	n.a.	PMID: 7629748
Unidentified anaerobic bacterium	Azetirelin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	n.a.	n.a.	Drug interaction:concentrations of the drug were maintained after the administration of antibiotic	PMID: 9279880
Bacteroides	1-b-D-arabinofuranosyl-5-(E)-(2-bromovinyl)uracil	Environmental Chemicals	Unclassified Substance	n.a.	BVU	n.a.	Rat	n.a.	The result of hydrolysis by anaerobic bacteria	Drug interaction: the drug with the anticancer drug 5-FU or prodrugs tegafur,5-FU accumulate(increase toxicity, including death)	PMID: 9808711
Unidentified gut microbes	Sulfanilamide	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	molecule sulfanilamide	Increase Efficacy	n.a.	n.a.	n.a.	Generate the active form of the drug	PMID: 31235939
Bacteroides thetaiotaomicron	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Mouse	Germ-free(GF)	Bt4096 encodes an enzyme that metabolizes diltiazem	n.a.	PMID: 31235939
Faecalibacterium	Anti‑PD‑1 therapy	Therapeutic Substance	Drug Class	n.a.	n.a.	n.a.	Human	Patients with melanoma	n.a.	Prolong progession-free survival	PMID: 31462078
Bacteroidetes	Checkpoint inhibitor therapy	Therapeutic Substance	Drug Class	n.a.	n.a.	Decrease Toxicity	n.a.	n.a.	Overabundance of the bacteroidetes phylum	Decrease occrrence of side effect	PMID: 31462078
Eggerthella lenta	Digoxin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	dihydrodigoxin	Decrease Bioavailability	Human	n.a.	A cytochrome-encoding operon (termed the cardiac glycoside reductase)	Convert to the inactive microbial metabolite;limit absorbtion;drug interaction:antibiotics,arginine-rich diet(impair this reaction)	PMID: 31462078
Unidentified gut microbes	Rosuvastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Human	Patients with with hyperlipidemia	Activity of bacteria containing bile salt hydrolases	Phyla Firmicutes、Fusobacteria（negatively associated with LDL-C levels）;Cyanobacteria、Lentisphaerae(positively)	PMID: 31462078
Firmicutes	Rosuvastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Human	n.a.	Bile salt hydrolase activity	Reduce LDL-C levels	PMID: 31462078
Lactobacillus reuteri	Rosuvastatin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Human	n.a.	Bile salt hydrolase activity	Reduce LDL-C levels	PMID: 31462078
Unidentified gut microbes	Irinotecan	Therapeutic Substance	Approved Drug	n.a.	SN-38	Increase Toxicity	n.a.	n.a.	Β-glucuronidases remove the glucuronide group;reactive the drug	Sever diarrhea;drug interaction(mice:oral administration of a specific inhibitor of the β-glucuronidase enzyme,reduce irinotecan-induced toxicity)	PMID: 31462078
Unidentified gut microbes	Dietary choline	Dietary Substance	Dietary Compounds	n.a.	trimethylamine-N-oxide(TMAO)	Increase Toxicity	n.a.	n.a.	Microbiome-derived metabolites	Interfer with drug pharmacokinetics and pharmacodynamics	PMID: 31462078
Unidentified gut microbes	Levocarnitine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	trimethylamine-N-oxide(TMAO)	Increase Toxicity	n.a.	n.a.	Microbiome-derived metabolites	Interfer with drug pharmacokinetics and pharmacodynamics	PMID: 31462078
Unidentified gut microbes	Acetylsalicylic acid	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	Damage the mucosa of the upper GI tract;be able to distinguish aspirin users:(Prevotella species, Bacteroides species, a member of the Ruminococaceae family, and Barnesiella species	PMID: 31462078
Unidentified gut microbes	Amlodipine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Human; Rat	n.a.	Presystemic metabolism by dehydrogenation	Decreased amount of active drug reaching target tissues;its major metabolite increased;drug interaction:rat(pretreated with ampicillin),enhance amlodipine's absorption;	PMID: 31462078
Unidentified gut microbes	Atorvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Human; Rat	Rat(high-fat diet);hypercholesterolemia patients	Decreased amount of secondary bile acids	Increase abundance of putative anti-inflammatory species	PMID: 31462078
Unidentified gut microbes	Captopril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	Rat	Hypertensive	Decreased intestinal permeability and fibrosis; and improved villi length	Reverse the dysbiotic state	PMID: 31462078
Unidentified gut microbes	Clonazepam	Therapeutic Substance	Approved Drug	n.a.	7-aminoclonazapam	n.a.	n.a.	n.a.	Reduction reactions	Drug interaction:antibiotics(inhibit)	PMID: 31462078
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	Decrease Efficacy	n.a.	n.a.	Microbial-derived bile acids competing for host uptake transporters	Decreased amount of drug reaching target tissues	PMID: 31462078
Unidentified gut microbes	Simvastatin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	Human	n.a.	Bacterial-derived bile acids(lithocholic acid,taurolithocholic acid,glycolithocholic acid)	Predict the magnitude of LDL-C lowering	PMID: 31462078
Unidentified gut microbes	Nitrazepam	Therapeutic Substance	Approved Drug	n.a.	7-amino-nitrazepam	Increase Toxicity	n.a.	n.a.	Nitro reduction by microbiota	Produce a teratogenic metabolite;drug interaction:antibiotics(inhibit)	PMID: 31462078
Bacteroides dorei DSM17855	Alfuzosin	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bifidobacterium ruminatum	Alprenolol	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bifidobacterium breve DSM20213	Benzbromarone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.828 [FDR-adjusted p-Value=0.049]	PMID: 31158845
Clostridium difficile 120	Camylofine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.05]	PMID: 31158845
Salmonella typhimurium LT2	Capecitabine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.688 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Blautia hansenii DSM20583	Clemizole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Bifidobacterium ruminatum	Diphenylpyraline	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Eubacterium rectale ATCC33656	Ethoxzolamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bifidobacterium ruminatum	Irsogladine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis ATCC43859	Lofexidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides uniformis ATCC8492	Metitepine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Blautia hansenii DSM20583	Orphenadrine citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Bacteroides dorei DSM17855	Oxcarbazepine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Bacteroides dorei DSM17855	Papaverine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Clostridium sp.	Paroxetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.378 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides coprophilus DSM18228	Rizatriptan benzoate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides fragilis HMW610	Sulpiride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.399 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Bacteroides fragilis 3397 T10	Trimetazidine dihydrochloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Verapamil	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Zidovudine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.952 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Bacteroides uniformis ATCC8492	Acecainide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis ATCC43859	Acecainide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.345 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Blautia hansenii DSM20583	Anastrozole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium sp.	Anastrozole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Blautia hansenii DSM20583	Benzthiazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Clostridium sp.	Benzthiazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis HMW610	Bicalutamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.612 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis HMW615	Bicalutamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Escherichia coli BW25113	Bupropion	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bifidobacterium ruminatum	Bupropion	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.682 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Clostridium sporogenes ATCC15579	Celecoxib	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Eubacterium biforme DSM3989	Celecoxib	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.898 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Blautia hansenii DSM20583	Cyclobenzaprine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Clostridium sp.	Cyclobenzaprine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.449 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Imatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Anaerostipes sp.	Imatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Bifidobacterium ruminatum	Memantine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Eubacterium biforme DSM3989	Memantine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.046]	PMID: 31158845
Clostridium sp.	Methsuximide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.51 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Bacteroides dorei DSM17855	Methsuximide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Dorea formicigenerans ATCC27755	Methysergide maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Methysergide maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bifidobacterium ruminatum	Metoprolol tartrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.347 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides fragilis ATCC43859	Metoprolol tartrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.328 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Naftopidil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides fragilis HMW610	Naftopidil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.006 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Blautia hansenii DSM20583	Nevirapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium sp.	Nevirapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Blautia hansenii DSM20583	Thiothixene	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.577 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Clostridium sp.	Thiothixene	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Tranilast	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides fragilis HMW610	Tranilast	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Blautia hansenii DSM20583	Vinpocetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Clostridium sp.	Vinpocetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Blautia hansenii DSM20583	Dipyridamole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Clostridium sp.	Dipyridamole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides dorei DSM17855	Dipyridamole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.805 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Blautia hansenii DSM20583	Doxazosin mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Clostridium sp.	Doxazosin mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides dorei DSM17855	Doxazosin mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Blautia hansenii DSM20583	Enalapril maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.439 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Enalapril maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.049]	PMID: 31158845
Eubacterium biforme DSM3989	Enalapril maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Blautia hansenii DSM20583	Fluvoxamine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Clostridium sp.	Fluvoxamine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bifidobacterium ruminatum	Fluvoxamine maleate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Blautia hansenii DSM20583	Sildenafil citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.494 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Clostridium sp.	Sildenafil citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.524 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium difficile 120	Sildenafil citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.424 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Sumatriptan succinate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides fragilis DS-208	Sumatriptan succinate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis HMW610	Sumatriptan succinate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Warfarin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.049]	PMID: 31158845
Bacteroides fragilis HMW615	Warfarin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides fragilis ATCC43859	Warfarin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Escherichia coli BW25113	Ziprasidone mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Ziprasidone mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Alistipes indistinctus DSM 22520	Ziprasidone mesylate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides uniformis ATCC8492	Amantadine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.378 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bifidobacterium ruminatum	Amantadine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.422 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Amantadine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.347 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides fragilis DS-208	Amantadine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Blautia hansenii DSM20583	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Alistipes indistinctus DSM 22520	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.327 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Eubacterium biforme DSM3989	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides fragilis HMW615	Cyclophosphamide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.046]	PMID: 31158845
Bacteroides coprophilus DSM18228	Ergotamine tartrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.956 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides WH2 WH2	Ergotamine tartrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Ergotamine tartrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.23 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Bacteroides fragilis DS-208	Ergotamine tartrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.969 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Escherichia coli BW25113	Mefloquine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.977 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Providencia alcalifaciens DSM30120	Mefloquine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Roseburia intestinalis L1-82	Mefloquine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Eggerthella lenta ATCC25559	Mefloquine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.995 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Clostridium sp.	Penbutolol sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.44 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Penbutolol sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides uniformis ATCC8492	Penbutolol sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Eubacterium biforme DSM3989	Penbutolol sulfate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Clostridium sp.	Pimozide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Anaerotruncus colihominis DSM17241	Pimozide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.725 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Pimozide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Pimozide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.128 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Tadalafil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Tadalafil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.547 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Bacteroides fragilis HMW610	Tadalafil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.523 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis HMW615	Tadalafil	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.434 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Blautia hansenii DSM20583	Biperiden	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.385 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Clostridium sp.	Biperiden	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.361 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Bacteroides dorei DSM17855	Biperiden	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.488 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Biperiden	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.583 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Blautia hansenii DSM20583	Methylphenidate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium sp.	Methylphenidate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.538 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bifidobacterium ruminatum	Methylphenidate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Eggerthella lenta ATCC25559	Methylphenidate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Blautia hansenii DSM20583	Ethopropazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Clostridium sp.	Ethopropazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides dorei DSM17855	Ethopropazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Ethopropazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Odoribacter splanchnius	Ethopropazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides dorei DSM17855	Phenytoin sodium	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Phenytoin sodium	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Phenytoin sodium	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Phenytoin sodium	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.326 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides uniformis ATCC8492	Phenytoin sodium	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Blautia hansenii DSM20583	Trihexyphenidyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Clostridium sp.	Trihexyphenidyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.526 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides dorei DSM17855	Trihexyphenidyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.386 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides uniformis ATCC8492	Trihexyphenidyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.331 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Bifidobacterium ruminatum	Trihexyphenidyl	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides dorei DSM17855	Cimetidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides uniformis ATCC8492	Cimetidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Cimetidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Cimetidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides fragilis 3397 T10	Cimetidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides fragilis T(B)9	Cimetidine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Blautia hansenii DSM20583	Dasatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.38 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Clostridium sp.	Dasatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Dasatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.327 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Dasatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.961 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bifidobacterium ruminatum	Dasatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis HMW610	Dasatinib	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Blautia hansenii DSM20583	Nafronyl oxalate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.049]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Nafronyl oxalate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.581 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Nafronyl oxalate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides uniformis ATCC8492	Nafronyl oxalate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bifidobacterium ruminatum	Nafronyl oxalate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Odoribacter splanchnius	Nafronyl oxalate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Odoribacter splanchnius	Olanzapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.708 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides coprophilus DSM18228	Olanzapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.538 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis 3397 T10	Olanzapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.057 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides fragilis T(B)9	Olanzapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides fragilis HMW610	Olanzapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides fragilis HMW615	Olanzapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Blautia hansenii DSM20583	Anagrelide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.398 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Clostridium sp.	Anagrelide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides dorei DSM17855	Anagrelide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Anagrelide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Odoribacter splanchnius	Anagrelide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.431 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Eubacterium biforme DSM3989	Anagrelide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides fragilis T(B)9	Anagrelide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.346 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides dorei DSM17855	Bezafibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.382 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Bezafibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.486 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Bezafibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.554 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Odoribacter splanchnius	Bezafibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.437 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Parabacteroides merdae ATCC43184	Bezafibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis HMW610	Bezafibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides fragilis ATCC43859	Bezafibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.709 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Blautia hansenii DSM20583	Carbetapentane citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Clostridium sp.	Carbetapentane citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Bacteroides dorei DSM17855	Carbetapentane citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.344 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Carbetapentane citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides uniformis ATCC8492	Carbetapentane citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Odoribacter splanchnius	Carbetapentane citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Victivallis vadensis ATCC BAA-548	Carbetapentane citrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.649 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Blautia hansenii DSM20583	Chlormezanone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Clostridium sp.	Chlormezanone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Chlormezanone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Clostridium asparagiforme DSM15981	Chlormezanone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.331 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bifidobacterium ruminatum	Chlormezanone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Alistipes indistinctus DSM 22520	Chlormezanone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Eubacterium biforme DSM3989	Chlormezanone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.412 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides dorei DSM17855	Dicyclomine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.817 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Dicyclomine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.585 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Dicyclomine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Pretovella copri DSM18205	Dicyclomine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Ruminococcus torques ATCC27756	Dicyclomine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.695 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Dicyclomine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Eggerthella lenta ATCC25559	Dicyclomine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides eggerthii DSM20697	Fenofibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.545 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Proteus penneri ATCC35198	Fenofibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.417 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Pretovella copri DSM18205	Fenofibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.516 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Clostridium asparagiforme DSM15981	Fenofibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.559 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Fenofibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.05 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Clostridium difficile 120	Fenofibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.308 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis T(B)9	Fenofibrate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.855 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Blautia hansenii DSM20583	Itraconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.527 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Clostridium sp.	Itraconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.649 [FDR-adjusted p-Value=0.049]	PMID: 31158845
Bacteroides uniformis ATCC8492	Itraconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.82 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Itraconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.067 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Blautia luti DSM14534	Itraconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.827 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Odoribacter splanchnius	Itraconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.136 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Clostridium sporogenes ATCC15579	Itraconazole	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.204 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Escherichia coli BW25113	Nicergoline	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.477 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Blautia hansenii DSM20583	Nicergoline	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Clostridium sp.	Nicergoline	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Nicergoline	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides uniformis ATCC8492	Nicergoline	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.698 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Clostridium difficile 120	Nicergoline	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.744 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Salmonella typhimurium LT2	Nicergoline	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.567 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Ramipril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.41 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Ramipril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.65 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Ramipril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides uniformis ATCC8492	Ramipril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Eubacterium biforme DSM3989	Ramipril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.377 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis T(B)9	Ramipril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Bacteroides fragilis ATCC43859	Ramipril	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.692 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides dorei DSM17855	Ooscapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Ruminococcus torques ATCC27756	Ooscapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Lactobacillus reuteri CF48-3A BEI HM-102	Ooscapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.343 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Providencia alcalifaciens DSM30120	Ooscapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bryantia formatexigens DSM 14469	Ooscapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Alistipes indistinctus DSM 22520	Ooscapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.378 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Eubacterium biforme DSM3989	Ooscapine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Escherichia coli BW25113	Oorgestimate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.713 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Blautia hansenii DSM20583	Oorgestimate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.162 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Clostridium sp.	Oorgestimate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.328 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Coprococcus comes ATCC27758	Oorgestimate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.324 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Oorgestimate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.486 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bifidobacterium ruminatum	Oorgestimate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.704 [FDR-adjusted p-Value=0.046]	PMID: 31158845
Eubacterium biforme DSM3989	Oorgestimate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.47 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Eggerthella lenta ATCC25559	Oorgestimate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.287 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Clostridium hathewayi DSM13479	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bifidobacterium breve DSM20213	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.878 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Enterococcus faecalis V583	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis T(B)9	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides fragilis DS-208	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides fragilis HMW610	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides fragilis HMW615	Ranitidine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Escherichia coli BW25113	Duloxetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Blautia hansenii DSM20583	Duloxetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Clostridium sp.	Duloxetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides dorei DSM17855	Duloxetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Enterobacter cancerogenus ATCC35316	Duloxetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.343 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Bacteroides uniformis ATCC8492	Duloxetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.345 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides ovatus ATCC8483	Duloxetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides coprophilus DSM18228	Duloxetine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.843 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides dorei DSM17855	Dexamethasone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium scindens ATCC35704	Dexamethasone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.605 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Dexamethasone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides uniformis ATCC8492	Dexamethasone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides stercoris ATCC43183	Dexamethasone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.336 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Dexamethasone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.363 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides fragilis DS-208	Dexamethasone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis HMW610	Dexamethasone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides fragilis ATCC43859	Dexamethasone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides dorei DSM17855	Glipizide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Glipizide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.751 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Odoribacter splanchnius	Glipizide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides coprophilus DSM18228	Glipizide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Eubacterium biforme DSM3989	Glipizide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.027]	PMID: 31158845
Bacteroides fragilis 3397 T10	Glipizide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.62 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides fragilis T(B)9	Glipizide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.693 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides fragilis HMW610	Glipizide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.77 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis ATCC43859	Glipizide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.801 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Blautia hansenii DSM20583	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.492 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Clostridium sp.	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.476 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides dorei DSM17855	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.713 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Odoribacter splanchnius	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis DS-208	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.355 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides fragilis HMW610	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.554 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides fragilis ATCC43859	Mifepristone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides caccae ATCC43185	Pericyazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.937 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides dorei DSM17855	Pericyazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.453 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Pericyazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.656 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Pericyazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.701 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Pericyazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Alistipes indistinctus DSM 22520	Pericyazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.857 [FDR-adjusted p-Value=0.05]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Pericyazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Pericyazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides fragilis HMW610	Pericyazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Escherichia coli BW25113	Primaquine phosphate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Primaquine phosphate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.531 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium bolteae ATCCBAA-613	Primaquine phosphate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.817 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Clostridium symbiosum ATCC14940	Primaquine phosphate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium spiroforme DSM1552	Primaquine phosphate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.549 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Primaquine phosphate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.808 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Primaquine phosphate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.673 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bifidobacterium breve DSM20213	Primaquine phosphate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Clostridium difficile 120	Primaquine phosphate	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Bacteroides dorei DSM17855	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.521 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.561 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.355 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides uniformis ATCC8492	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.521 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Odoribacter splanchnius	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Eubacterium biforme DSM3989	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.868 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Bacteroides fragilis HMW610	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.68 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides fragilis HMW615	Drospirenone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Clostridium sp.	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.19 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Collinsella aerofaciens ATCC25986	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Anaerococcus hydrogenalis DSM7454	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Clostridium symbiosum ATCC14940	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.324 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Ruminococcus lactaris ATCC29176	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Eubacterium hallii DSM3353	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.736 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides coprophilus DSM18228	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.44 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Eubacterium rectale ATCC33656	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bryantia formatexigens DSM 14469	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Eggerthella lenta ATCC25559	Eszopiclone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Escherichia coli BW25113	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.081 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Blautia hansenii DSM20583	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides dorei DSM17855	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.188 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.906 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Anaerostipes sp.	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.751 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Eubacterium ventriosum ATCC27560	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.029 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.37 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Pretovella copri DSM18205	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides uniformis ATCC8492	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.767 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Roseburia intestinalis L1-82	Fluphenazine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.81 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Clostridium sp.	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Bacteroides dorei DSM17855	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.651 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides uniformis ATCC8492	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.798 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Bacteroides fragilis T(B)9	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Bacteroides fragilis DS-208	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.737 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides fragilis HMW610	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.74 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Bacteroides fragilis ATCC43859	Ketorolac tromethamine	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.764 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Blautia hansenii DSM20583	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.539 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium sp.	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides dorei DSM17855	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.518 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides uniformis ATCC8492	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.545 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bifidobacterium ruminatum	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.377 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Odoribacter splanchnius	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Eubacterium biforme DSM3989	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.336 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis HMW610	Oxybutynin chloride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Escherichia coli BW25113	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides uniformis ATCC8492	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.572 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Odoribacter splanchnius	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.661 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.509 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.411 [FDR-adjusted p-Value=0.049]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.47 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Eggerthella lenta ATCC25559	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.36 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides fragilis DS-208	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides fragilis HMW615	Paclitaxel	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides dorei DSM17855	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Bacteroides uniformis ATCC8492	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.748 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Odoribacter splanchnius	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.38 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis HMW610	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.508 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis HMW615	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.508 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis ATCC43859	Repaglinide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Pretovella copri DSM18205	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.371 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Bacteroides uniformis ATCC8492	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.529 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides ovatus ATCC8483	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.629 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.545 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.681 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis 3397 T10	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.701 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis DS-208	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.629 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides fragilis HMW610	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.896 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides fragilis HMW615	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides fragilis ATCC43859	Sotalol	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.907 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Blautia hansenii DSM20583	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Clostridium sp.	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides dorei DSM17855	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.807 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides uniformis ATCC8492	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Bacteroides fragilis HMW610	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Bacteroides fragilis HMW615	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis ATCC43859	Zaleplon	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.568 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Clostridium sp.	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides uniformis ATCC8492	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.865 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides stercoris ATCC43183	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Odoribacter splanchnius	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.644 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Clostridium sporogenes ATCC15579	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.872 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.417 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides fragilis 3397 T10	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Bacteroides fragilis T(B)9	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.036]	PMID: 31158845
Bacteroides fragilis DS-208	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.531 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Bacteroides fragilis HMW615	Ezetimibe	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides dorei DSM17855	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.491 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Odoribacter splanchnius	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.411 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis 3397 T10	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.473 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides fragilis DS-208	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.423 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis HMW610	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Bacteroides fragilis HMW615	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides fragilis ATCC43859	Gliclazide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides dorei DSM17855	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.852 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.737 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides uniformis ATCC8492	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.069 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides stercoris ATCC43183	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bifidobacterium ruminatum	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.52 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides ovatus ATCC8483	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis 3397 T10	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.529 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides fragilis HMW610	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.759 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Bacteroides fragilis HMW615	Rebamipide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.767 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Escherichia coli BW25113	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Odoribacter splanchnius	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.638 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Eggerthella lenta ATCC25559	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.912 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Bacteroides fragilis DS-208	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides fragilis HMW610	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.681 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides fragilis HMW615	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides fragilis ATCC43859	Sulfinpyrazone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.724 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Blautia hansenii DSM20583	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.406 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides uniformis ATCC8492	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.791 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Odoribacter splanchnius	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.51 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.473 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides fragilis 3397 T10	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides fragilis T(B)9	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.596 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides fragilis DS-208	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.023]	PMID: 31158845
Bacteroides fragilis HMW615	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.783 [FDR-adjusted p-Value=0.042]	PMID: 31158845
Bacteroides fragilis ATCC43859	Etodolac	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.814 [FDR-adjusted p-Value=0.015]	PMID: 31158845
Bacteroides dorei DSM17855	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.723 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.735 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.592 [FDR-adjusted p-Value=0.031]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides uniformis ATCC8492	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.589 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Akkermansia muciniphila ATCC BAA-835	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.039 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Odoribacter splanchnius	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.496 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides fragilis DS-208	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides fragilis HMW610	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides fragilis HMW615	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.564 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Bacteroides fragilis ATCC43859	Finasteride	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides uniformis ATCC8492	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.495 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides ovatus ATCC8483	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.494 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides coprophilus DSM18228	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.627 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.019]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.589 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides fragilis 3397 T10	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis T(B)9	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides fragilis DS-208	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.563 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis HMW610	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.67 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides fragilis HMW615	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis ATCC43859	Galantamine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Bacteroides dorei DSM17855	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.782 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.721 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides uniformis ATCC8492	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides fragilis 3397 T10	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides fragilis T(B)9	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.038]	PMID: 31158845
Bacteroides fragilis DS-208	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.037]	PMID: 31158845
Bacteroides fragilis HMW615	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.585 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Bacteroides fragilis ATCC43859	Griseofulvin	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Blautia hansenii DSM20583	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Clostridium sp.	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides dorei DSM17855	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.828 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.764 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides pectinophilus ATCC43243	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.525 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.047]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides uniformis ATCC8492	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Bacteroides fragilis HMW610	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis HMW615	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides fragilis ATCC43859	Metaxalone	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.014]	PMID: 31158845
Pretovella copri DSM18205	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Bacteroides uniformis ATCC8492	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides ovatus ATCC8483	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.722 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides coprophilus DSM18228	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.98 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.548 [FDR-adjusted p-Value=0.045]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.723 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides fragilis 3397 T10	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.924 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis T(B)9	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.839 [FDR-adjusted p-Value=0.018]	PMID: 31158845
Bacteroides fragilis DS-208	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.898 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis HMW610	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.708 [FDR-adjusted p-Value=0.0]	PMID: 31158845
Bacteroides fragilis ATCC43859	Naloxone	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.155 [FDR-adjusted p-Value=0.016]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides uniformis ATCC8492	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.454 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Odoribacter splanchnius	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides fragilis 3397 T10	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.032]	PMID: 31158845
Bacteroides fragilis T(B)9	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.005]	PMID: 31158845
Bacteroides fragilis HMW610	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Bacteroides fragilis HMW615	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.569 [FDR-adjusted p-Value=0.039]	PMID: 31158845
Bacteroides fragilis ATCC43859	Naproxen(+)	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides dorei DSM17855	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.007]	PMID: 31158845
Bacteroides uniformis ATCC8492	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.568 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides ovatus ATCC8483	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.62 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Parabacteroides merdae ATCC43184	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides coprophilus DSM18228	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.008]	PMID: 31158845
Bacteroides thetaiotaomicron 3731	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.352 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Bacteroides fragilis 3397 T10	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.693 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides fragilis T(B)9	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Bacteroides fragilis DS-208	Neostigmine bromide	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.013]	PMID: 31158845
Bacteroides dorei DSM17855	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.999 [FDR-adjusted p-Value=0.006]	PMID: 31158845
Bacteroides cellulosilyticus DSM14838	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.567 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.856 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.73 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.886 [FDR-adjusted p-Value=0.041]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.784 [FDR-adjusted p-Value=0.03]	PMID: 31158845
Bacteroides uniformis ATCC8492	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.005 [FDR-adjusted p-Value=0.009]	PMID: 31158845
Bacteroides stercoris ATCC43183	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.04]	PMID: 31158845
Odoribacter splanchnius	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.035]	PMID: 31158845
Bacteroides ovatus ATCC8483	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.029]	PMID: 31158845
Bacteroides thetaiotaomicron 7330	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.619 [FDR-adjusted p-Value=0.022]	PMID: 31158845
Bacteroides fragilis HMW610	Telmisartan	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.615 [FDR-adjusted p-Value=0.017]	PMID: 31158845
Blautia hansenii DSM20583	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.371 [FDR-adjusted p-Value=0.002]	PMID: 31158845
Clostridium sp.	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides dorei DSM17855	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.647 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides vulgatus ATCC8482	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.028]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.048]	PMID: 31158845
Bacteroides fragilis NCTC 9343	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.034]	PMID: 31158845
Bacteroides uniformis ATCC8492	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Odoribacter splanchnius	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.359 [FDR-adjusted p-Value=0.021]	PMID: 31158845
Bacteroides fragilis 3397 T10	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.024]	PMID: 31158845
Bacteroides fragilis T(B)9	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.495 [FDR-adjusted p-Value=0.033]	PMID: 31158845
Bacteroides fragilis DS-208	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Bacteroides fragilis HMW610	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.01]	PMID: 31158845
Bacteroides fragilis ATCC43859	Colchicine	Therapeutic Substance; Herbal Substance	Approved Drug; Medicinal Herbal Compounds	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.574 [FDR-adjusted p-Value=0.026]	PMID: 31158845
Blautia hansenii DSM20583	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.043]	PMID: 31158845
Clostridium sp.	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.044]	PMID: 31158845
Bacteroides dorei DSM17855	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.011]	PMID: 31158845
Parabacteroides johnsonii DSM18315	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.012]	PMID: 31158845
Parabacteroides distasonis ATCC8503	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.828 [FDR-adjusted p-Value=0.003]	PMID: 31158845
Bacteroides xylanisolvens DSM18836	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.781 [FDR-adjusted p-Value=0.001]	PMID: 31158845
Bacteroides uniformis ATCC8492	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.02]	PMID: 31158845
Bacteroides ovatus ATCC8483	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.207 [FDR-adjusted p-Value=0.004]	PMID: 31158845
Alistipes indistinctus DSM 22520	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High-throughput incubation assays	n.a.	n.a.	Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.401 [FDR-adjusted p-Value=0.025]	PMID: 31158845
Bacteroides thetaiotaomicron VPI-5482	Diltiazem	Therapeutic Substance	Approved Drug	n.a.	n.a.	n.a.	High